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(57) ABSTRACT 
The invention is directed to methods and compositions for 
inhibiting caspase-independent apoptosis. In particular, 
methods and compositions for inhibiting Omi/HtrA2 activity, 
as well as method for identifying other inhibitors of Omi/ 
HtrA2. Also disclosed are Omi/HtrA2 specific substrates and 
methods for identifying other substrates ofOmi/HtrA2. 
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METHOD AND COMPOUNDS FOR 
INHIBITION OF CELL DEATH 
RELATED CASE INFORMATION 
2 
prises the tetra peptide motif"AVPS" at its N terminus. It has 
been demonstrated that the deregulated expression of Omi/ 
HtrA2 in the cytoplasm of mammalian cells induces apopto-
sis in these cells, indicating that Omi/HtrA2 could participate 
in the mitochondrial apoptotic pathway. 
Mature Omi/HtrA2 is released from the mitochondria into 
the cytosol upon disruption of the outer mitochondrial mem-
brane during apoptosis. Mature Omi/HtrA2 can induce apo-
ptosis in human cells in a caspase-independent manner 
This is Continuation-In-Part application that claims prior-
ity to U.S. Provisional Patent Application No. 60/361,902, 
filed Feb. 28, 2002, and U.S. Utility patent application Ser. 
No. 10/369,311, filed Feb. 20, 2003, which are incorporated 
herein by their entirety. 10 through its protease activity and in a caspase-dependent man-
ner via its ability to disrupt caspase-IAP interaction. 
BACKGROUND OF THE INVENTION 
The technical field of this invention relates generally to 
alteration of apoptosis in a cell and modification of pathways 
involved in apoptosis including the treatment of diseases that 
involve apoptotic pathways. In particular, the invention per-
tains to a class of inhibitors that inhibit mitochondrial homeo-
stasis, caspase-dependent, and caspase-independent apopto-
sis by affecting Omi/HtrA2 activity. 
Since Omi/HtrA2 is present in all mammalian cells and by 
its activity of disrupting the inhibition of the "apoptosis pro-
tein-caspase interaction" decreases the cell lifetime, it would 
15 be important to discover an inhibitor of the adverse activity of 
Omi/HtrA2 and homologous proteins. 
Accordingly, it would be useful to identify a class ofinhibi-
tors that inhibit Omi/HtrA2. A need also exists to determine 
the peptides involved in the caspase-independent pathway of 
Apoptosis, which is also referred to as programmed cell 
death, is a form of cell death characterized by membrane 
blebbing and nuclear DNA fragmentation. Apoptotic cell 
death is morphologically distinct from necrotic cell death and 
20 apoptosis such as substrates ofOmi/HtrA2, as well as meth-
ods and compositions that inhibit such pathways. It would 
also be useful to find ways to use these methods and compo-
sitions to prevent, reduce or ameliorate a disorder associated 
with apoptosis. 
is important in the normal development and maintenance of 25 
multicellular organisms. 
Since apoptosis functions in maintaining tissue homeosta-
sis in a range of physiological processes such as embryonic 
development, immune cell regulation and normal cellular 
turnover, the dysfunction or loss of regulated apoptosis can 30 
lead to a variety of pathological disease states. For example, 
the loss of apoptosis can lead to the pathological accumula-
tion of self-reactive lymphocytes that occurs with many 
autoimmune diseases. Inappropriate loss or inhibition of apo-
ptosis can also lead to the accumulation of virally infected 35 
cells and of hyperproliferative cells such as neoplastic or 
tumor cells. Similarly, the inappropriate activation of apop-
tosis can also contribute to a variety of pathological disease 
states including, for example, acquired immunodeficiency 
syndrome (AIDS), neurodegenerative diseases and ischemic 40 
injury. Treatments that are specifically designed to modulate 
the apoptotic pathways in these and other pathological con-
ditions can alter the natural progression of many of these 
diseases. 
SUMMARY OF THE INVENTION 
The invention is based on the discovery that the activity of 
Omi/HtrA2 can be inhibited by a class of compounds referred 
to as "apoptosis inhibiting compounds." The mature serine 
protease Omi/HtrA2 was identified as a mitochondrial direct 
baculoviral inhibitor of apoptosis protein repeat3(BIR3)-
binding protein and a caspase activator (Hegde et al. (2002) J. 
Biol. Chem., 277: 432-438). The involvement of a mitochon-
drial serine protease in the apoptotic pathway emphasizes the 
role of the mitochondria in cell death. Therefore, the identi-
fication and use of apoptosis. These apoptotic inhibiting com-
pounds can be formulated into pharmaceutical compositions. 
The methods and compositions of the invention can be used to 
inhibit mitochondrial homeostasis, caspase-dependent, and 
caspase-independent apoptosis by affecting Omi/HtrA2 
activity. 
Accordingly, in one aspect the invention pertains to a phar-
maceutical composition for inhibiting cellular apoptosis, the 
composition comprising at least one apoptosis inhibiting 
compound that can modulate caspase-independent apoptosis. 
The pharmaceutical composition can further comprise a 
pharmaceutical acceptable excipient. In one embodiment, the 
apoptosis inhibiting compound, comprise the general struc-
Although apoptosis is mediated by diverse signals and 45 
complex interactions of cellular gene products, the results of 
these interactions ultimately feed into a cell death pathway 
that is evolutionarily conserved between humans and inver-
tebrates. The pathway, itself, is a cascade of proteolytic events 
analogous to that of the blood coagulation cascade. 
Several gene families and products that modulate the apo-
ptotic process have now been identified. Key to the apoptotic 
program is a family of cysteine proteases termed caspases. 
The human caspase family includes Ced-3, human ICE (in-
terleukin-I-beta converting enzyme) (caspase-1), ICH-1 55 
(caspase-2), CPP32 (caspase-3), ICEreZII(caspase-4), ICEreZII 
(caspase-5), Mch2 (caspase-6), ICE-LAP3 (caspase-7), 
Mch5 (caspase-8), ICE-LAP6 (caspase-9), Mch4 (caspase-
10), caspase 11-14, and others. Capsases can be positioned as 
downstream effectors of apoptosis. 
50 ture shown in FIG. la, where R1 is selected from the group 
consisting of a nitro group, a carboxy group, a hydroxide, an 
aliphatic group, an aromatic group, an acyl group, an alkoxy 
group, an alkylene group, an alkenylene group, an alkynylene 
group, a hydroxycarbonylalkyl group, an anhydride, an 
amide, an amine, and a heterocyclic aromatic group. In a 
preferred embodiment, the apoptosis inhibiting compound 
has the structure shown in FIG. lb. In another embodiment, 
the apoptosis inhibiting compound comprises the general 
structure shown in FIG. 2a where R1 is selected from the 
The serine protease Omi, is also involved in apoptosis. Omi 
(also known as "HtrA2" and "Omi/HtrA2") was identified as 
60 group consisting of a nitro group, a carboxy group, a hydrox-
ide, an aliphatic group, an aromatic group, an acyl group, an 
alkoxy group, an alkylene group, an alkenylene group, an 
alkynylene group, a hydroxycarbonylalkyl group, an anhy-a mitochondrial direct inhibitor of apoptosis protein (IAP) 
binding protein, and is released from the mitochondria upon 
induction of apoptosis by apoptotic stimuli (Hegde et al. 65 
(2002) J. Biol. Chem., 277: 432-438). The mature Omi/HtrA2 
protein contains a conserved !AP-binding motif that com-
dride, an amide, an amine, and a heterocyclic aromatic group. 
In a preferred embodiment, the apoptosis inhibiting com-
pound has the structure shown in FIG. 2b. In yet another 
embodiment, the apoptosis inhibiting compound comprises 
US 8,242,122 B2 
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the general structure shown in FIG. 3a, where R1 is selected 
from the group consisting of a nitro group, a carboxy group, 
a hydroxide, an aliphatic group, an aromatic group, an acyl 
group, an alkoxy group, an alkylene group, an alkenylene 
group, an alkynylene group, a hydroxycarbonylalkyl group, 
an anhydride, an amide, an amine, and a heterocyclic aro-
matic group. In a preferred embodiment, the apoptosis inhib-
iting compound has the structure shown in FIG. 3b. In yet 
another embodiment, the apoptosis inhibiting compound 
comprises the general structure shown in FIG. 4a, where R1 is 10 
selected from the group consisting of a nitro group, a carboxy 
group, a hydroxide, an aliphatic group, an aromatic group, an 
acyl group, an alkoxy group, an alkylene group, an alkenylene 
group, an alkynylene group, a hydroxycarbonylalkyl group, 
an anhydride, an amide, an amine, and a heterocyclic aro- 15 
matic group. In a preferred embodiment, the apoptosis inhib-
iting compound has the structure shown in FIG. 4b. 
The pharmaceutical composition may also comprise a mix-
ture of apoptosis inhibiting compounds as long as the apop-
tosis inhibiting compounds in the mixture can modulate 20 
caspase-independent apoptosis. For example, the composi-
tion may have any combinations of the compounds shown in 
FIGS. 1-4. 
4 
can be associated with the proximal tubules of the kidney, and 
may cause renal apoptosis and/or renal ischeamia. 
In yet another aspect, the invention pertains to a method for 
identifying a substrate associated with caspase-independent 
apoptosis, comprising contacting a cell extract with recom-
binant Omi/HtrA2, wherein the recombinant Omi/HtrA2 has 
proteolytic activity. The results from the contacted cell extract 
can be compared with the results of the with a control sample 
that has not been incubated with recombinant Omi/HtrA2. A 
substrate associated with caspase-independent apoptosis can 
be identified by monitoring a change in the electophoretic 
mobility of a protein in the cell extract incubated with recom-
binant Omi/HtrA2, such that a change in electophoretic 
mobility of the protein indicates that the protein is a substrate 
ofOmi/HtrA2. The change in electophoretic mobility can be 
the disappearance of a protein in the cell extract incubated 
with recombinant Omi/HtrA2. In one embodiment, the pro-
tein associated with caspase-independent apoptosis is 
obtained from a kidney cell extract. Preferably, the protein 
associated with caspase-independent apoptosis is a substrate 
for Omi/HtrA2. In one embodiment, the substrate associated 
with caspase-independent apoptosis is 14-3-3. In another 
embodiment, the substrate associated with caspase-indepen-In another aspect, the invention pertains to a method for 
inhibiting caspase-independent apoptosis in a cell by contact-
ing a cell having Omi/HtrA2 activity with at least one apop-
tosis inhibiting compound, such that the apoptosis inhibiting 
compound interacts with Omi/HtrA2 to inhibit the activity of 
Omi/HtrA2, wherein the inhibition of Omi/HtrA2 activity 
reduces apoptosis in the cell; and monitoring the inhibition of 
apoptosis. 
25 dent apoptosis is Annexin V. 
In yet another embodiment, the invention pertains to a 
method for identifying a compound that inhibits caspase-
independent apoptosis, comprising contacting the candidate 
compound with a substrate coupled to a fluorescent marker in 
The inhibiting compound can selected from the group con-
sisting of the structure shown in FIG. la, FIG. 2a, FIG. 3a and 
FIG. 4a. Preferably, the apoptosis inhibiting compound has 
the structure shown in FIG. lb, FIG. 2b, FIG. 3b, and FIG. 4b. 
30 the presence of recombinant Omi/HtrA2, wherein the recom-
binant Omi/HtrA2 has proteolytic activity against the sub-
strate, and monitoring the change in fluorescence, whereby a 
candidate compound is identified as being an inhibitor of 
In yet another aspect, the invention pertains to a method of 
inhibiting Omi/HtrA2 activity, comprising contacting a cell 
having Omi/HtrA2 activity with an apoptosis inhibiting com-
pound; and monitoring the inhibition of Omi/HtrA2 activity. 
The cell to be contacted can either be an in vitro cell or an in 
vivo cell. The apoptosis inhibiting compound can be anyone 
of the aforementioned inhibitors. The step of monitoring 
Omi/HtrA2 activity can be by monitoring a change in fluo-
rescene of an Omi/HtrA2 substrate coupled to a fluorescent 
marker, or by monitoring the inhibition of Omi/HtrA2 activ-
ity further comprises monitoring apoptosis of the cell. 
35 
caspase-independent apoptosis if the candidate compound 
inhibits or blocks the proteolytic activity of recombinant 
Omi/HtrA2. The substrate can be a specific Omi/HtrA2 sub-
strate selected from the group consisting of 14-3-3 and 
annexin V. Alternatively, the substrate can be a general sub-
40 strate such as casein. The fluorescent marker can be selected 
from the group consisting of fluorescein isothiocyanate 
(FITC), cyanine dye-5 (CY5), cyanine dye-3 (Cy3), cyanine 
dye-7 (Cy7), allophycocyanin (APC), tetramethyl rhodamine 
isothiocyanate (TRITC), and phycoerythrin (PE). Preferably, 
45 the fluorescent marker is FITC. The recombinant Omi/HtrA2 
In yet another aspect, the invention pertains to a method for 
modifying a disorder associated with caspase-independent 
apoptosis comprising administering a therapeutically effec-
tive amount of a composition comprising at least one apop- 50 
tosis inhibiting compound such that the apoptosis inhibiting 
compound interacts with Omi/HtrA2 to inhibit the activity of 
Omi/HtrA2, wherein the inhibition of Omi/HtrA2 activity 
reduces apoptosis in the cell; and monitoring the amelioration 
of the disorder by measuring the change in caspase-indepen- 55 
dent apoptosis. The disorder can be selected from the group 
consisting of kidney failure, heart failure, heart attack, stroke, 
neurodegenerative disease, cancers and tumors. In a preferred 
embodiment, the disorder is kidney failure. 
In yet another aspect, the invention pertains to a method of 60 
preventing tubular cell death, comprising administering an 
apoptosis inhibiting compound, wherein the apoptosis inhib-
iting compound interacts with Omi/HtrA2 such that the apo-
ptosis inhibiting compound interacts with Omi/HtrA2 to 
inhibit the activity of Omi/HtrA2, wherein the inhibition of 65 
Omi/HtrA2 activity prevents tubular cell death; and monitor-
ing the prevention of tubular cell death. The tubular cell death 
is MBP-Omi134_458 
BRIEF DESCRIPTION OF FIGURES 
FIG. la is the general structure of an apoptosis inhibiting 
compound, and FIG. lb is the specific structure ofUcf 101; 
FIG. 2a is the general structure of an apoptosis inhibiting 
compound, and FIG. 2b is the specific structure ofUcf 102; 
FIG. 3a is the general structure of an apoptosis inhibiting 
compound, and FIG. 3b is the specific structure ofUcf 103; 
FIG. 4a is the general structure of an apoptosis inhibiting 
compound, and FIG. 4b is the specific structure ofUcf 104; 
FIG. 5 is a schematic drawing showing caspase-dependent 
and caspase-independent pathways involving Omi/HtrA2; 
FIG. 6 is a schematic drawing showing the functional 
domains ofOmi/HtrA2; 
FIG. 7 is a graph showing the inhibition of MBP-Omi 
(134-458) in the presence of ucf-101 and several other ucf 
analogs(•, ucf-101; +, ucf-102; e, ucf-103, .._, ucf-104); 
FIG. 8 is a photograph of an SDS-PAGE gel showing the in 
vitro proteolytic activity ofMBP-Omi (134-458) in the pres-
ence of different concentrations of ucf 101; 
US 8,242,122 B2 
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FIG. 9 is a graph showing the inhibition of proteolytic 
activity ofMBP-Omi (134-458) and MBP-L56 (14-480) ( +, 
MBP-Omi; •, MBP-L56); 
FIG. 10 is a bar graph showing the inhibition of Omi-
induced caspase independent cell death by ucf-101 ; 
FIG. lla is a photograph of Western blot showing that the 
protein levels of Omi/HtrA2 increases in MPT cells induced 
with various cisplatin and antimycin apoptotic stimuli, while 
FIG. llb shows the increase in the presence of hydrogen 
peroxide; 
FIG. 12 is a bar graph showing that ucf-101 blocks cispl-
atin-induced apoptosis in MPT cells; 
FIG. 13 is a schematic drawing showing the different Omi 
constructs; 
FIG. 14 is a photograph of an SDS-PAGE gel showing the 
expression and processing of the various Omi constructs; and 
FIG. 15 is a bar graph showing the results of an apoptosis 
assay using the various Omi constructs; 
DETAILED DESCRIPTION 
The practice of the present invention employs, unless oth-
erwise indicated, conventional methods of virology, microbi-
ology, molecular biology and recombinant DNA techniques 
within the skill of the art. Such techniques are explained fully 
in the literature. (See, e.g., Sambrook, et al. Molecular Clon-
ing: A Laboratory Manual (Current Edition); DNA Cloning: 
A Practical Approach, Vol. I & II (D. Glover, ed.); Oligo-
nucleotide Synthesis (N. Gait, ed., Current Edition); Nucleic 
Acid Hybridization (B. Hames & S. Higgins, eds., Current 
Edition); Transcription and Translation (B. Hames & S. Hig-
gins, eds., Current Edition); CRC Handbook of Parvoviruses, 
Vol. I & II (P. Tijessen, ed.); Fundamental Virology, 2nd 
Edition, Vol. I & II (B. N. Fields and D. M. Knipe, eds.)) 
So that the invention is more clearly understood, the fol-
lowing terms are defined: 
The term "apoptosis" as used herein refers to the art rec-
ognized use of the term for an active process of programmed 
cell death characterized by morphological changes in the cell. 
Apoptosis is characterized by membrane blebbing and 
nuclear DNA fragmentation. Apoptosis can occur via two 
pathways, the caspase-dependent pathway, where involves 
caspases where Omi/HtrA2 interacts with an inhibitor of 
apoptosis protein (IAP) and activates the caspase pathway. 
Alternatively, apoptosis can occur via the caspase-indepen-
dent pathway, where Omi/HtrA2 acts as a serine protease and 
does not involve caspases. 
The phrase "inhibitor of apoptosis protein (IAP)" as used 
herein referres to the art recognized use of the phrase for a 
protein that contains at least one copy ofBaculovirus IAP of 
a repeat (BIR) domain and suppresses apoptosis when over-
expressed and is known to bind and inhibit caspases. 
The term "zymogen" as used herein refers to the inactive 
proform of an enzyme e.g. a caspase, which is typically 
activated by proteolysis. 
6 
"TY"), Caspase-6 (also known as "Mch2"), Caspase-7 (also 
known as "Mch3 ," "ICE-LAP3" "CMH-1 "), Caspase-8 (also 
known as "FLICE;" "MACH;" "Mch5"), Caspase-9 (also 
known as "I CE-LAP6;" "Mch6"), Caspase-10 (also known as 
"Mch4," "FLICE-2"). 
The phrase "caspase-dependent apoptosis" as used herein 
refers to an apoptosis pathway that involves caspases. In a 
caspase-dependent apoptosis pathway, mature Omi/HtrA2 
comprising the tetrapeptide motif "AVPS" which binds to 
10 x-chromosome linked InhibitorofApoptosis Protein (XIAP), 
and causes caspase activation, which results in apoptosis. 
The phrase "caspase-independent apoptosis" as used 
herein refers to apoptosis pathway that does not involves 
caspases. Instead, Omi/HtrA2 behaves like a serine protease 
15 exhibiting proteolytic activity. When Omi/HtrA2 functions as 
a protease, it proteolytically cleaves specific protein sub-
strates leading to apoptosis. 
The term "apoptosis inhibiting compound" as used herein 
refers to an agent that can reduce apoptosis by a detectable 
20 amount by acting on a pathway involved in apoptosis. The 
agent can act by inhibiting or blocking a particular step in the 
apoptotic pathway, for example by blocking or inhibiting the 
activity of protein involved in the pathway, such as inhibiting 
the activity of Omi/HtrA2. The apoptotic pathway includes 
25 both caspase-dependent apoptosis, as well as caspase-inde-
pendent apoptosis. In a preferred embodiment, the apoptosis 
inhibiting compound acts on the caspase-independent apop-
tosis pathway to reduce or inhibit apoptosis by a detectable 
amount. Examples of apoptosis inhibiting compounds, 
30 include, but are not limited to those structures shown in FIG. 
la, FIG. 2a, FIG. 3a, and FIG. 4a. Preferred apoptosis inhib-
iting compounds are referred to as "U cf-101" (shown in FIG. 
lb), "Ucf-102" (shown in FIG. 2b), "Ucf-103" (shown in 
FIG. 3b) and "Ucf 104" (shown in FIG. 4b). A particularly 
35 preferable apoptosis inhibiting compound is Ucf 101. Also 
within the scope of the invention are the use of combinations 
and mixtures of apoptosis inhibiting compounds, for 
example, a mixture comprising Ucf-101 and Ucf-102; Ucf-
101, Ucf-102, and Ucf-103; or Ucf-101, Ucf-102, Ucf-103 
40 and Ucf 104, or any combinations thereof. 
The term "inhibit" or "inhibiting" as used herein refers to a 
measurable reduction of apoptotic activity. Preferably a 
reduction of activity of at least about 20%. More preferably 
the reduction of activity is about 30%, 40%, 50%, 60%, 80%, 
45 90% and even more preferably, about 100%. 
The term "modulate" or "modify" are used interchange-
ably herein and refer to an alleviation of at least one target 
protein or gene involved in the caspase-independent path-
way for apoptosis. Such that apoptosis is inhibited or reduced. 
50 A target protein can be for example, Omi/Htr2A. Modifica-
tion of the Omi/Htr2A may occur when an apoptosis inhibit-
ing compound interacts with Omi/Htr2A an alters the func-
tional activity of Omi/Htr2A. A modification in apoptosis can 
be assessed by monitoring cell blebbing DNA fragmentation, 
55 and the like. 
The term "caspase" as used herein refers to a cysteine 
protease that specifically cleaves proteins after Asp residues. 
Caspases are initially expressed as zymogens, in which a 
large subunit is N-terminal to a small subunit. Caspases are 
generally activated by cleavage at internal Asp residues. 60 
Caspases are found in a myriad of organisms, including 
human, mouse, insect (e.g., Drosophila), and other inverte-
brates (e.g., C. elegans). The caspases include, but are not 
limited to, Caspase-1 (also known as "ICE"), Caspase-2 (also 
known as "ICH-1"), Caspase-3 (also known as "CPP32," 65 
"Yama," "apopain"), Caspase-4 (also known as "ICE.rezIJ'; 
"TX," "ICH-2"), Caspase-5 (also known as "ICE.rezIJ'; 
The phrase "a disorder associated with Omi/Htr2A activ-
ity" or "a disease associated with Omi/Htr2A activity" as 
used herein refers to any disease state associated with the 
expression of Omi/Htr2A. Examples include but are not lim-
ited to kidney failure, ischemia-reperfusion injury, heart fail-
ure, neurodegeneration disorders such as Alzheimer's dis-
ease, Parkinson's disease, Huntington's disease and 
amytrophic lateral sclerosis; inflanimation; osteoarthritis; 
human immunodeficiency virus); bacterial infection, cell 
proliferative disorders, cancers, and diabetes. 
The term "subject" as used herein refers to any living 
organism in which an immune response is elicited. The term 
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subject includes, but is not limited to, humans, nonhuman 
primates such as chimpanzees and other apes and monkey 
species; farm animals such as cattle, sheep, pigs, goats and 
horses; domestic mammals such as dogs and cats; laboratory 
animals including rodents such as mice, rats and guinea pigs, 
and the like. The term does not denote a particular age or sex. 
Thus, adult and newborn subjects, as well as fetuses, whether 
male or female, are intended to be covered. 
The invention is described in more detail in the following 
sections: 
I. Apoptosis and Omi/HtrA2 
In one aspect, the invention pertains to reducing, inhibiting, 
preventing or altering apoptosis, particularly caspase-inde-
pendent apoptosis. Apoptosis or programmed cell death was 
originally described by Kerr et al., in 1972 (Kerr, et al. (1972) 
Br J Cancer, 26, 239-57), as a new cell-autonomous mecha-
nism of death aimed at removing damaged, mutated or aged 
cells. Mitochondria, are directly linked to the process of apo-
ptosis to the extent that they are now termed "killer 
organelles" (Ravagnan, et al. (2002) J Cell Physiol, 192, 
131-7). Mitochondria contain several proteins in their inter-
membrane space which are released in response to pro-apo-
ptotic stimuli. These diverse proteins include cytochrome c, 
AIF, Smac/Diablo, endonuclease G and Omi/HtrA2 (See e.g., 
Van Loo, et al. (2002) Cell Death Differ, 9, 1031-42). Each of 
these proteins has a distinct function but they are all pro-
apoptotic and, invariably, their release from the mitochondria 
induces cell death. Omi/HtrA2, the most recent member of 
this group, was originally isolated and characterized as a new 
members of the stress-signaling pathway (Faccio, et al. 
(2000) J. Biol. Chem., 275, 2581-8). Omi/HtrA2 has high 
sequence homology to bacterial HtrAs, proteins that act as 
chaperones at normal temperatures and as proteases at 
elevated temperatures to remove damaged or denatured pro-
teins (Fallen, et al. (1997) Mal. Microbial., 26, 209-21). 
Omi/HtrA2 is a human serine protease that has extensive 
homology to bacterial high temperature requirement A 
(HtrA) proteins (Faceio et al. (2000) J. Biol. Chem. 275, 
2581-2588; and Gray et al. (2000) Eur., J. Biochem. 267, 
5699-5710). Bacterial HtrAs have a dual function, acting as 
chaperones at normal temperatures and as proteases at 
elevated temperatures and removing damaged or denatured 
proteins, allowing the recovery and survival of bacteria fol-
lowing stress (Fallen et al. (1997) Mal. Microbial. 26, 209-
221; and Spiess et al. (1999) Cell 97, 339-347). 
Mammalian Omi/HtrA is a ubiquitous protein, although 
tissue-specific alternatively spliced forms have been reported 
(Gray et al. (2000) Eur., J. Biochem. 267, 5699-5710; and 
Faccio et al. (2000) Genomics 68, 343-347). Recent studies 
described Omi as a mitochondrial protein that upon induction 
of apoptosis is released to the cytoplasm where it binds XIAP 
(X chromosome-linked inhibitor of apoptosis protein) result-
ing in caspase-9 activation (Suzuki et al. (2001) Mal. Cell. 8, 
613-621; Hegde et al. (2002) J. Biol. Chem. 277, 432-438; 
Martins eta!. (2002)J. Biol. Chem. 277, 439-444; Verhagen et 
al. (2002) J. Biol. Chem. 277, 445-454; and van Loo et al. 
(2002) Cell Death Differ. 9, 20-26). In this regard, Omi 
resembles Smac/DIABLO, which also binds IAPs and as a 
result activates caspase-9 (Flu et al. (2000) Cell I 02, 33-42; 
and Verhagen et al. (2000) Cell 102, 43-53). 
Omi/HtrA2 protein is synthesized as a precursor that is 
processed in the mitochondria to produce the mature protein. 
This processing exposes an internal tetrapeptide motif, 
AVPS, at the amino terminus. A similar motif is found in all 
!AP-binding proteins, including the Drosophila Grim, 
Reaper, Hid, and Sickle (Chen et al. (1996) Genes Dev. 10, 
1773-1782; Vucic et al. (1997) Proc. Nail. Acad. Sci. U.S.A. 
8 
94, 10183-10188; Vucic et al. (1998) Mal. Cell. Biol. 18, 
3300-3309; and Srinivasula et al. (2002) Cur. Biol. 12, 125-
130). 
Omi/HtrA2 is present in the mitochondria and is released 
5 to the cytoplasm upon induction ofapoptosis. In this capacity, 
Omi/HtrA2 is unique both in its structure as well as its func-
tion. In the cytoplasm, Omi/HtrA2 can induce apoptosis 
through a caspase-dependent as well as in a caspase-indepen-
dent pathway. 
10 Omi/HtrA2 belongs to a family of mammalian serine pro-
teases; its proteolytic activity is necessary for auto-process-
ing to expose the AVPS motif. Furthermore, Omi/HtrA2 can 
also induce apoptosis in a manner that does not depend on the 
AVPS motif but depends entirely on its ability to function as 
15 a protease (Suzuki, et al. (200l)Mol. Cell., 8, 613-21; Hegde, 
et al. (2002) J Biol Chem, 277, 432-8; Martins, et al. (2002)J. 
Biol. Chem., 277, 439-44; and Verhagen, et al. (2002) J. Biol. 
Chem., 277, 445-54). Thus suggests specific substrates for 
Omi/HtrA2 may exist and their cleavage (whether this leads 
20 to activation of a precursor or a destruction of a protein) may 
be a part of the apoptotic process. One other member of 
family of proteases is L56/HtrA1, is a serine protease that is 
overexpressed in osteoathritic cartilage (Hu, et al. (1998) J. 
Biol. Chem., 273, 34406-12) and is also repressed in fibro-
25 blasts following SV40 infection (Zumbrunn, et al. (1996) 
FEBSLett., 398, 187-92). ThesimilaritybetweenOmi/HtrA2 
and other proteins is restricted to their carboxyl terminus 
which includes the proteolytic domain and PDZ motif while 
the amino termini of the two proteins are different (Faccio, et 
30 al. (2000) J. Biol. Chem., 275, 2581-8). Unlike Omi/HtrA2, 
which remains intracellular, L56/HtrA1 is secreted (Faccio, 
et al. (2000) supra; and Hu, et al. (1998) J. Biol. Chem., 273, 
34406-12). 
When Omi/HtrA2 induces apoptosis in a caspase-indepen-
35 dent pathway, it does so by relying entirely on its ability to 
function as a serine protease (Suzuki et al. (2001) Mal. Cell. 
8, 613-621; Hegde et al. (2002) J. Biol. Chem. 277, 432-438; 
and Verhagen et al. (2002) J. Biol. Chem. 277, 445-454). 
Neitherthe mechanism nor the significance of this function of 
40 Omi/HtrA2 is clearly understood. 
Structurally, Omi/HtrA2 is a 458 amino acid polypeptide 
that was originally isolated as an interactor of Mxi2 kinase 
(Faccio, et al. (2000) J. Biol. Chem., 275, 2581-8). It was 
subsequently identified as an interactor of presenilin, a pro-
45 tein found mutated in some cases of Alzheimer's disease 
(Gray, et al. (2000)EurJ Biochem, 267, 5699-710). There are 
three distinct domains in the Omi/HtrA2 protein: a catalytic 
domain, a PDZ domain and an amino terminal domain (see 
FIG. 6). The amino-terminal domain carries a mitochondrial 
50 targeting sequence (MTS) and three copies of a motif 
PRAAXXTXX (SEQ ID No:l), where Xis any amino acid. 
The function of this motif is not yet known. This amino 
terminal domain of Omi (aa 1-133) is cleaved through an 
intra-molecular reaction to create the mature Omi/HtrA2 pro-
55 tein. The mature Omi/HtrA2 has a new exposed amino ter-
minal sequence (AVPS) that is similar to the sequence present 
in other known inhibitors of apoptosis (IAP)-binding proteins 
(See Table 1 ). This family of proteins includes the only other 
known IAP binding protein Smac/DIABLO (Du, et al. (2000) 
60 Cell, 102, 33-42; and Verhagen, et al. Cell, 102, 43-53), as 
well as three Drosophila proteins Reaper (Vucic, et al. (1997) 
Proc. Natl. Acad. Sci. USA, 94, 10183-8; and Vucic, et al. 
(1997) Mal Cell Biol, 17, 667-76), Hid (Vucic, et al. (1998) 
Mal Cell Biol, 18, 3300-9) and Grim (Chen, et al. (1996) 
65 Genes Dev, 10, 1773-82). Besides the presence of the IAP-
binding motif, no other similarity is found between these 
proteins. 
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TABLE 1 
Comparison of known !AP-binding motifs found in two 
mammalian (Omi/HtrA2 and Smac/DIABLO) and 











Omi/HtrA2 mRNA is expressed ubiquitously, and the gene 
is localized on human chromosome 2p12. Omi/HtrA2 inter-
acts with Mxi2, an alternatively spliced form of the p38 
stress-activated kinase and, when made in a heterologous 
system, shows proteolytic activity against a non-specific sub-
strate ~-casein. The proteolytic activity of Omi/HtrA2 is 
markedly up-regulated in the mouse kidney following 
ischemia/reperfusion. (See Examples) 
Therefore, Omi/HtrA2 promotes cell death via two differ-
ent pathways: one that relies on IAP binding and inhibition 
and involves caspase activation, and the second which 
depends on its proteolytic activity and is caspase-indepen-
dent. (See FIG. 5) 
Alternative forms of Omi/HtrA2 are also within the scope 
of the invention and include alternative splice forms and their 
encoded polypeptides. In one embodiment, the alternatively 
spliced form of Omi/HtrA2 is D-Omi that is expressed pre-
dominantly in the kidney (See Examples). To identify the 
origin of this alternatively spliced form, the genomic locus of 
Omi/HtrA2 was characterized and found to be present on the 
human chromosome 2p 12. Omi gene consists of eight exons, 
two of them are absent in the kidney specific D-Omi. D-Omi 
is not able to bind to the Mxi2 protein due to its modified PDZ 
domain. Furthermore, D-Omi has no detectable proteolytic 
activity when tested against ~-casein, a generic substrate. 
D-Omi lacks the amino acid sequence encoded by two 
exons and is structurally quite distinct from Omi/HtrA2. It 
has a modified PDZ domain and shows no detectable pro-
teolytic activity. The data shown in the Examples section 
suggest that D-Omi may have a unique function, different 
from Omi/HtrA2, in the tissues where it is expressed. D-Omi 
may also function in apoptosis and it may have role in modu-
lating cellular events following tubular cell injury, such as 
renal tubule cell injury. 
Variants of the Omi/HtrA2 nucleic acid molecules and the 
proteins they encode are also within the scope of the inven-
tion, these include natural variants (e.g., polymorphisms, 
splice variants or mutants) and those produced by genetic 
engineering (e.g., substitutions, deletions or addition ofresi-
dues ). Many methods for generating mutants have been 
developed (see generally, Ausubel et al., supra). Preferred 
methods include alanine scanning mutagenesis and PCR gen-
eration of mutants using an oligonucleotide containing the 
desired mutation to amplify mutant nucleic acid molecules. 
Variants generally have at least 70% or 75% nucleotide iden-
tity to the native sequence, preferably at least 80%-85%, and 
most preferably at least 90%, 92%, 93%, 94%, 95%, 96%, 
97%, 98% or 99% nucleotide identity. 
10 
ing: A Laboratory Manual, Cold Spring Harbor Press, 1989). 
Typically, homologous polynucleotide sequences can be con-
firmed by hybridization under stringent conditions, as is 
known in the art. For example, using the following wash 
conditions: 2xSSC (0.3 M NaCl, 0.03 M sodium citrate, pH 
7.0), 0.1 % SDS, room temperature twice, 30 minutes each; 
then 2.times.SSC, 0.1 % SDS, 50° C. once, 30 minutes; then 
2xSSC, room temperature twice, 10 minutes each, homolo-
gous sequences can be identified which contain at most about 
10 25-30% basepair mismatches. More preferably, homologous 
nucleic acid strands contain 15-25% basepair mismatches, 
even more preferably 5-15% basepair mismatches. 
The term "homology" or "identity" or "homologous" as 
used herein refers to the percentage oflikeness between mol-
15 ecules. To determine the homology or percent identity of two 
amino acid sequences or of two nucleic acid sequences, the 
sequences are aligned for optimal comparison purposes (e.g., 
gaps can be introduced in one or both of a first and a second 
amino acid or nucleic acid sequence for optimal alignment 
20 and non-homologous sequences can be disregarded for com-
parison purposes). In a preferred embodiment, the length of a 
reference sequence aligned for comparison purposes is at 
least 30%, preferably at least 40%, more preferably at least 
50%, even more preferably at least 60%, and even more 
25 preferably at least 70%, 80%, or 90% of the length of the 
reference sequence. The amino acid residues or nucleotides at 
corresponding amino acid positions or nucleotide positions 
are then compared. When a position in the first sequence is 
occupied by the same amino acid residue or nucleotide as the 
30 corresponding position in the second sequence, then the mol-
ecules are identical at that position (as used herein amino acid 
or nucleic acid "identify" is equivalent to amino acid or 
nucleic acid "homology"). The percent identify between the 
two sequences is a function of the number of identical posi-
35 tions shared by the sequences, taking into account the number 
of gaps, and the length of each gap, which need to be intro-
duced for optimal alignment of the two sequences. 
The comparison of sequences and determination of percent 
identify between two sequences can be accomplished using a 
40 mathematical algorithm. For example, the percent identity 
between two amino acid sequences can be determined using 
the Needleman and Wunsch (1970) J. Mal. Biol. (48):444-
453) algorithm which has been incorporated into the GAP 
program in the GCG software package (available at http:// 
45 www.gcg.com), using either a Blossom 62 matrix or a 
PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 
anda length weight of 1, 2, 3, 4, 5, and 6. In another example, 
the percent identify between two nucleotide sequences is 
determined using the GAP program in the GCG software 
50 package (available at http://www.gcg.com), using a NWS-
gapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 
and a length weight of 1, 2, 3, 4, 5, or 6. In yet another 
example, the percent identify between two amino acid or 
nucleotide sequences is determined using the algorithm ofE. 
55 Meyers and W. Miller (CABIOS, 4:11-17 (1989)) which has 
been incorporated into the ALIGN program (version 2.0), 
using a PAMl 20 weight residue table, a gap length penalty of 
12 and a gap penalty. 
III. Omi/HtrA2 and Tubular Cell Death 
Further, a nucleotide variant will typically be sufficiently 60 
similar in sequence to hybridize to the reference sequence 
under moderate or stringent hybridization conditions. For 
nucleic acid molecules over about 500 bp, stringent condi-
tions include a solution comprising about 1 MNa+ at25 to 30° 
In one aspect, the invention pertains to inhibiting tubular 
cell death by modifying apoptosis, preferably by modifying 
caspase-independent apoptosis. In a particularly preferred 
embodiment, the methods and compositions of the invention 
can be used for acute renal failure (ARF). 
C. below the Tm; e.g., 5xSSPE, 0.5% SDS, at 65 C.; see 65 
Ausubel et al., Current Protocols in Molecular Biology, 
Greene Publishing, 1995; Sambrook et al., Molecular Clan-
ARF is a serious medical problem that occurs in 5% of all 
hospitalized patients. The prognosis of ARF is poor, has 
remained unchanged over the past three decades, and carries 
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a high mortality rate of about 50%. AlthoughARF is the result 
of many causes, the most common cause is injury to the renal 
tubular epithelial cells (RTEC). 
The invention relates to the role of Omi/HtrA2 in the apo-
ptotic cell death that occurs in RTEC, as well as the molecular 
events that follow its activation leading to apoptosis. By 
blocking the activity of Omi/HtrA2 using a specific inhibitor, 
a new approach to protect and maintain cell viability is avail-
able. 
The cell death that follows renal injury is both apoptotic as 
well as necrotic (Lieberthal, et al. (1998) Semin Nephrol, 18, 
505-18). The relative contribution of these two forms of cell 
death to tubular necrosis is not yet known. It depends both on 
the nature as well as severity of insult. Severe injury (e.g. 
ishcedmic injury) usually triggers necrosis whereas milder 
insults to the kidney cause apoptotic death of the RTEC. 
Necrosis is difficult to prevent but apoptosis can potentially 
12 
hours after ischemia/reperfusion as well as in MPT cells 
treated with antimycin or cisplatin (inducers of apoptosis). 
The amount of Omi/HtrA2 protein increases dramatically 
after ischemic or chemical injury in the mouse kidneys or 
MPT cells. Furthermore, inhibiting the proteolytic activity of 
Omi/HtrA2 using the ucf-101 inhibitor protects MPT cells 
from cisplatin-induced apoptosis. 
Though not bound by any theory, Omi/HtrA2 may exert its 
caspase-independent effect by proteolytic cleavage of poten-
10 tial substrates leading to the destruction and removal of the 
substrates as part of this process. Alternatively, Omi/HtrA2, 
through specific proteolytic cleavage, might activate precur-
sor proteins that are part of the caspase-independent apoptotic 
process. 
15 IV. Inhibitors 
be modulated to maintain cell viability. Therefore, identify-
ing the different components of the apoptotic pathway, espe-
cially the ones that play a major role in kidney, provides new 20 
information on the apoptotic process. These new components 
can also provide specific and novel targets for intervention to 
help patients with acute renal failure. 
In one aspect, the invention pertains to using inhibitors of 
caspase-independent apoptosis. In order to investigate the 
caspase-independent mechanism of apoptosis initiated by 
Omi/HtrA2, specific inhibitors of its proteolytic activity were 
isolated. One such family of synthetic compounds was iden-
tified and described in the Examples section. In one embodi-
ment, the apoptosis inhibiting compound include the class of 
heterocyclic compounds referred to as 1,3 diphenyl-5-(sub-
stituted)-2-thioxo-dihydropyrimidine-4,6-dione derivatives. 
In a preferred embodiment, the apoptosis inhibiting com-
pound has the general structure shown in FIG. la, where R1 , 
depicts the various side chains which can include, but are not 
limited to a nitro group, a carboxy group, a hydroxide, an 
aliphatic group, an aromatic group, an acyl group, an alkoxy 
group, an alkylene group, an alkenylene group, an alkynylene 
group, a hydroxycarbonylalkyl group, an anhydride, an 
amide, an amine, and a heterocyclic aromatic group. In a 
preferred embodiment, the apoptosis inhibiting compound 
has the structure shown in FIG. lb and is referred to as 
Most of the previous studies on tubular apoptosis have 
focused on the role of caspases and their activation and have 25 
utilized caspase-specific inhibitors in an attempt to inhibit 
apoptosis and protect tubular cells from ischemic as well as 
toxic insults (See e.g., Ueda, et al. (2000) Am J Med, 108, 
403-15; and Ueda, et al. (2000) Nephrol Dial Transplant, 15, 
318-23). Omi/HtrA2 is a pro-apoptotic protease and is the 30 
only protein identified thus far that is able to cause apoptosis 
in a caspase-dependent as well as caspase-independent man-
ner. The caspase-independent pathway is not yet clearly 
understood but relies on the ability of Omi/HtrA2 to function 
as a serine protease. 
Table 2 lists known inducers of apoptosis of tubular cells in 
acute renal failure. Caspases have been shown to be activated 
both by ischemic as well as cytotoxic insults to cultured 
RTECs (Lau, et al. (1999) Kidney Int, 56, 1295-8; Hortelano, 
et al. (2000) J Am Soc Nephrol, 11, 2315-23; van de Water, et 
al. (2000)J Biol Chem, 275, 25805-13. 2000; and Kaushal, et 
al. (2001) Kidney Int, 60, 1726-36) as well as kidney cells in 
vivo (Daemen, et al. (2001) Transplantation, 71, 778-84; Shi, 
35 "ucf-101". 
In another embodiment, the apoptosis inhibiting com-
pound has a general structure shown in FIG. 2a, where R1 is 
a nitro group, a carboxy group, a hydroxide, an aliphatic 
group, an aromatic group, an acyl group, an alkoxy group, an 
40 alkylene group, an alkenylene group, an alkynylene group, a 
hydroxycarbonylalkyl group, an anhydride, an amide, an 
amine, and a heterocyclic aromatic group. In a preferred 
embodiment the apoptosis inhibiting compound has the struc-
ture shown in FIG. 2b and is referred to as "ucf-102". et al. (2000) Am J Physiol, 279, F509-l 7; Sano, et al. (2000) 
Kidney Int, 57, 1560-70; and Bonventre, (1998) Kidney & 45 
Blood Pressure Research, 21, 226-9). Furthermore, inhibition 
In another embodiment, the apoptosis inhibiting com-
pound has the general structure shown in FIG. 3a, where R 1 is 
a nitro group, a carboxy group, a hydroxide, an aliphatic 
group, an aromatic group, an acyl group, an alkoxy group, an 
alkylene group, an alkenylene group, an alkynylene group, a 
of caspases ameliorates ischemia-reperfusion injury in the 
kidney (Daemen, et al. (1999) J Clin Invest, 104, 541-9). 
TABLE2 
Potential causes of apoptosis of tubular cells in acute renal failure 






Grow factor deficiency: Rapamycin 
Loss of cell-matrix adhesion, Loss of cell-cell 
adhesion 
Ischemia!hypoxia: Oxidant stress 
Phannacologic agents: Cisplatin, Aminoglycosides, 
Amphotericin B 
Fas-FasL: TNF-a-TNF Receptor type 1, 
Angiotensin 11-angiotensin II receptor type 
2 (ATR2) 
50 hydroxycarbonylalkyl group, an anhydride, an amide, an 
amine, and a heterocyclic aromatic group. In preferred 
embodiment, the apoptosis inhibiting compound has the 
structure shown in FIG. 3b and is referred to as "ucf-103." 
In another embodiment, the apoptosis inhibiting com-
55 pound has the general structure shown in FIG. 4, where R1 is 
a nitro group, a carboxy group, a hydroxide, an aliphatic 
group, an aromatic group, an acyl group, an alkoxy group, an 
alkylene group, an alkenylene group, an alkynylene group, a 
hydroxycarbonylalkyl group, an anhydride, an amide, an 
60 amine, and a heterocyclic aromatic group. In preferred 
embodiment, the apoptosis inhibiting compound has the 
structure shown in FIG. 4b and is referred to as "ucf-104". Omi/HtrA2 plays a role in the apoptosis that occurs in 
RTECs following renal injury. The data in the Examples 
section shows that Omi/HtrA2 is predominantly expressed in 
the proximal tubular cells in both human and mouse kidneys. 65 
This area of the kidney is most susceptible to ischemic injury. 
The protein level of Omi/HtrA2 increased dramatically 24 
These class ofheterocyclic compounds showed significant 
and specific activity against the protease in an in vitro assay. 
The compound from this family, which exhibited the highest 
activity against Omi/HtrA2 is ucf-101. The results clearly 
showed ucf-101 had a profound effect on the activity of 
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Omi/HtrA2 and could substantially inhibit its ability to 
induce caspase-independent apoptosis in caspase-9 (-/-)null 
fibroblasts. The results clearly showed ucf-101 had a pro-
found effect on the activity ofOmi/HtrA2 and could substan-
tially inhibit its ability to induce caspase-independent apop-
tosis in caspase-9 (-/-)null fibroblasts. 
U cf-101 naturally fluoresces and easily enters mammalian 
cells, allowing its use in in vivo experiments. The ucf-101 
inhibitor can therefore be used as a tool to dissect the two 
different activities ( caspase-dependent versus caspase-inde-
pendent) ofOmi and their respective contribution to apopto-
sis in various biological settings. Furthermore, ucf-101, or a 
similar compound, may be useful as an anti-apoptotic drug 
that would specifically target caspase-independent cell death 
under clinical conditions. 
V. Omi/HtrA2 Substrates 
In one aspect, the invention pertains to identifying sub-
strates involved in caspase-independent apoptosis. In particu-
lar, the identification of substrates of Omi/HtrA2. To identify 
Omi/HtrA2 substrates an assay for substrates can be per-
formed. In general, assays are designed to evaluate apoptotic 
pathway activation (e.g., caspase protein processing, caspase 
enzymatic activity protease activity, cell viability, cell mor-
phology changes, DNA laddering, and the like). In any of the 
assays, a statistically significant increase or decrease com-
pared to a proper control is indicative of enhancement or 
inhibition. In a preferred embodiment, apoptosis is monitored 
by an electrophoresis method (e.g., 2D gel electrophoresis), 
where the presence, absence or disappearance if a protein is 
measured. In such an assay, cell extracts are incubated with 
recombinant Omi/HtrA2 (test sample) and without Omi/ 
HtrA2 (control sample). After incubation, the cell extracts are 
examined by electrophoresis (e.g., 2D electrophoresis). Typi-
cally, the presence of a protein in the control sample, and its 
subsequent disappearance (or the degradation into smaller 
fragments) in the test sample, identifies the presence of a 
specific Omi/HtrA2 substrate in the cell extract. The disap-
pearance of the protein band indicates that the protein is a 
specific substrate of Omi/HtrA2 which has been degraded by 
the protease activity ofOmi/HtrA2. 
Using this assay, the data shown in the Examples section 
identifies two substrates for Omi/HtrA2. In one embodiment, 
the Omi/HtrA2 substrate is the 14-3-3 protein. In another 
embodiment, the Omi/HtrA2 substrate is annexin V. The data 
shows that the two polypeptides were specifically cleaved by 
Omi/HtrA2 and their degradation was inhibited by the spe-
cific inhibitor ucf-101. Annexin V and 14-3-3 proteins were 
shown to be involved in both apoptosis and intracellular sig-
naling. 
VI. Screening for Inhibitor or Enhancers 
In one aspect, the invention pertains to identifying inhibi-
tors of apoptosis, particularly inhibitors of caspase-indepen-
dent apoptosis. In particular, the identification of inhibitors of 
Omi/HtrA2. Candidate inhibitors may be isolated or procured 
from a variety of sources, such as bacteria, fungi, plants, 
parasites, libraries of chemicals, peptides or peptide deriva-
tives, antibodies, and the like. Inhibitors may also be ratio-
nally designed, based on the protein structures determined 
from X-ray crystallography. 
Without wishing to be bound to a particular theory or held 
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activity ofOmi/HtrA2 when it acts as a serine protease Inhibi-
tors may include small molecules (organic molecules), pep-
tides, polypeptides, and antibodies, for example. In one 
embodiment, the inhibitors prevent apoptosis. Inhibitors 
should have a minimum of side effects and are preferably 
non-toxic. 
Screening assays for inhibitors will vary according to the 
type of inhibitor and the nature of the activity that is being 
affected. Assays may be performed in vitro or in vivo. In 
10 general, assays are designed to evaluate apoptotic pathway 
activation (e.g., caspase protein processing, caspase enzy-
matic activity, serine protease activity cell viability, cell mor-
phology changes, DNA laddering, and the like). In any of the 
assays, a statistically significant increase or decrease com-
15 pared to a proper control is indicative of enhancement or 
inhibition. In a preferred embodiment, apoptosis is monitored 
by a fluorescent method. Typically, an increase in cell viabil-
ity as compared to a control indicates the presence of an 
inhibitor, while a decrease in cell viability as compared to a 
20 control indicates the presence of an enhancer. 
For a caspase-independent in vitro assay, a substrate of 
Omi/HtrA2 is fluorescently labeled with fluorescent marker 
(e.g. FITC), and fluorescently labeled substrate is incubated 
with recombinant Omi/HtrA2 (e.g., MPB-Omi134_458). The 
25 fluorescent activity of substrate is measured using a fluores-
cent microscopy or a fluorescemeter. As the Omi/HtrA2 pro-
tease acts on the substrate, a change in the fluorescence can be 
measured. Using this fluorescent assay, inhibitor and enhanc-
ers ofOmi/HtrA2 can be used and the change in fluorescence 
30 in the presence of an inhibitor or enhancer can be measured. 
To facilitate detection using the fluorescent method with a 
substrate labeled with a fluorescent marker (e.g., FITC, and 
the like) the substrate can be examined by fluorescence 
microscopy. Candidate compounds may be obtained from a 
35 variety of sources. For example, they may be produced 
recombinantly, purified from a natural source, or synthesized. 
Alternatively, candidate molecules may be identified by 
screening a library of compounds such as those available 
form Nanoysn. The preferred compound will be one that is 
40 able to inhibit apoptosis, preferably caspase-independent 
apoptosis. The candidate compounds can be at least partially 
purified, and most preferably, candidate compounds will be 
purified to near homogeneity. Appropriate controls depend 
upon the source of the candidate compound and might 
45 include, for example, extracts from cells transfected with 
control vector, or storage or reaction buffers. 
For a caspase-dependent in vitro assay detecting inhibitors 
and enhancers of caspase-mediated apoptosis can be per-
formed by examining the effect of a candidate compound on 
50 the activation of an initiator caspase (e.g., caspase 9) or an 
effectorcaspase (e.g., caspases 3-7). Briefly, procaspase 9, an 
IAP, cytochrome c, dATP, and an Omi peptide, polypeptide, 
functional variant, or functional equivalent are provided. The 
processing of caspase-9 into two subunits is assayed. Alter-
55 natively, caspase-9 enzymatic activity is monitored by adding 
procaspase-3, procaspase-7, or other effector caspases to the 
reaction mix and monitoring the activation of these caspases, 
for example, either via subunit formation or via cleavage of a 
substrate (e.g., acetyl DEVD-aminomethyl coumarin (amc), 
60 lamin, PRPP, PARP, and the like). Typically, an increase in 
processing to subunits indicates the presence of an enhancer, 
while a decrease in processing to subunits indicates the pres-
ence of an inhibitor. 
to a particular mechanism, an inhibitor may act by preventing 
Omi/HtrA2 release from the mitochondria, interfering with 
Omi/HtrA2 binding to an IAP, inhibiting Omi/HtrA2 pro-
tease activity, or by other mechanisms. If the caspase depen-
dent pathway is involved, the inhibitor may act to prevent 65 
caspase activity. Alternatively, if the capase-independent 
pathway is involved, the inhibitor may inhibit the proteolytic 
Also, for caspase-dependent apoptosis a candidate com-
pound may be used for binding assays. A candidate com-
pound may be added to a binding reaction with an Omi 
binding molecule and recombinant Omi/HtrA2 peptide or 
US 8,242,122 B2 
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polypeptide, and its ability to inhibit Omi/HtrA2 binding to 
an Omi-binding molecule can be determined by comparing 
binding in the presence or absence of a candidate compound. 
In certain circumstances, such assays will detect displace-
ment or inhibition of binding of an Omi-binding molecule 
from an Omi peptide or polypeptide. 
16 
(BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). 
In all cases, the composition must be sterile and should be 
fluid to the extent that easy syringability exists. It must be 
stable under the conditions of manufacture and storage and 
must be preserved against the contaminating action of micro-
organisms such as bacteria and fungi. The carrier can be a 
solvent or dispersion medium containing, for example, water, 
ethanol, polyol (for example, glycerol, propylene glycol, and 
liquid polyethylene glycol, and the like), and suitable mix-
tures thereof. The proper fluidity can be maintained, for 
example, by the use of a coating such as lecithin, by the 
maintenance of the required particle size in the case of dis-
In vivo assays are typically performed in cells transfected 
either transiently or stably with an expression vector contain-
ing an Omi/HtrA2 nucleic acid molecule such as those 
described herein. These cells may be used to measure caspase 10 
processing, caspase substrate turnover, enzymatic activity of 
effector caspases, or apoptosis in the presence or absence of a 
candidate compound. When assaying apoptosis, a variety of 
methods of cell analyses may be used, including, for example, 
fluorescent spectroscopy and electro-proteins dye staining 
and microscopy to examine cell viability, nucleic acid frag-
mentation, porosity of the cells, and membrane blebbing. 
15 persion and by the use of surfactants. Prevention of the action 
20 
A variety of methodologies exist that can be used to inves-
tigate the effect of a candidate compound. Such methodolo-
gies are those commonly used to analyze enzymatic reactions 
and include, for example, SDS-PAGE, 2D-gel electrphoresis, 
fluorescent spectroscopy, fluorescent microscopy, HPLC 
analysis, autoradiography, chemiluminescence, chromoge-
nic reactions, and immunochemistry (e.g., blotting, precipi-
25 
tating, etc.). 
VII Pharmaceutical Compositions 
The apoptosis inhibiting compound can be incorporated 
into pharmaceutical compositions suitable for administration 
to a subject, e.g., a human. Such compositions typically com-
30 
prise the apoptosis inhibiting compound and a pharmaceuti-
cally acceptable carrier. 
As used herein the language "pharmaceutically acceptable 
carrier" is intended to include any and all solvents, dispersion 
media, coatings, antibacterial and antifungal agents, isotonic 
35 
and absorption delaying agents, and the like, compatible with 
pharmaceutical administration. The use of such media and 
agents for pharmaceutically active substances is well known 
in the art. Except insofar as any conventional media or agent 
is incompatible with the active compound, such media can be 
40 
used in the compositions of the invention. Supplementary 
active compounds can also be incorporated into the compo-
sitions. A pharmaceutical composition of the invention is 
formulated to be compatible with its intended route ofadmin-
istration. Examples of routes of administration include 
45 
parenteral, e.g., intravenous, intradermal, subcutaneous, oral 
(e.g., inhalation), transdermal (topical), transmucosal, and 
rectal administration. Solutions or suspensions used for 
parenteral, intradermal, or subcutaneous application can 
include the following components: a sterile diluent such as 
50 
water for injection, saline solution, fixed oils, polyethylene 
glycols, glycerine, propylene glycol or other synthetic sol-
vents; antibacterial agents such as benzyl alcohol or methyl 
parabens; antioxidants such as ascorbic acid or sodium bisul-
fate; chelating agents such as ethylenediaminetetraacetic 
55 
acid; buffers such as acetates, citrates or phosphates and 
agents for the adjustment of tonicity such as sodium chloride 
or dextrose. pH can be adjusted with acids or bases, such as 
hydrochloric acid or sodium hydroxide. The parenteral prepa-
ration can be enclosed in ampules, disposable syringes or 
60 
multiple dose vials made of glass or plastic. 
Pharmaceutical compositions suitable for injectable use 
include sterile aqueous solutions (where water soluble) or 
dispersions and sterile powders for the extemporaneous 
preparation of sterile injectable solutions or dispersion. For 65 
intravenous administration, suitable carriers include physi-
ological saline, bacteriostatic water, Cremophor EL™ 
of microorganisms can be achieved by various antibacterial 
and antifungal agents, for example, parabens, chlorobutanol, 
phenol, ascorbic acid, thimerosal, and the like. In many cases, 
it will be preferable to include isotonic agents, for example, 
sugars, polyalcohols such as manitol, sorbitol, sodium chlo-
ride in the composition. Prolonged absorption of the inject-
able compositions can be brought about by including in the 
composition an agent which delays absorption, for example, 
aluminum monostearate and gelatin. 
Sterile injectable solutions can be prepared by incorporat-
ing the active compound (e.g., a receptor protein or anti-
receptor antibody) in the required amount in an appropriate 
solvent with one or a combination of ingredients enumerated 
above, as required, followed by filtered sterilization. Gener-
ally, dispersions are prepared by incorporating the active 
compound into a sterile vehicle which contains a basic dis-
persion medium and the required other ingredients from those 
enumerated above. In the case of sterile powders for the 
preparation of sterile injectable solutions, the preferred meth-
ods of preparation are vacuum drying and freeze-drying 
which yields a powder of the active ingredient plus any addi-
tional desired ingredient from a previously sterile-filtered 
solution thereof. 
Oral compositions generally include an inert diluent or an 
edible carrier. They can be enclosed in gelatin capsules or 
compressed into tablets. For oral administration, the agent 
can be contained in enteric forms to survive the stomach or 
further coated or mixed to be released in a particular region of 
the GI tract by known methods. For the purpose of oral 
therapeutic administration, the active compound can be 
incorporated with excipients and used in the form of tablets, 
troches, or capsules. Oral compositions can also be prepared 
using a fluid carrier for use as a mouthwash, wherein the 
compound in the fluid carrier is applied orally and swished 
and expectorated or swallowed. Pharmaceutically compatible 
binding agents, and/or adjuvant materials can be included as 
part of the composition. The tablets, pills, capsules, troches 
and the like can contain any of the following ingredients, or 
compounds of a similar nature: a binder such as microcrys-
talline cellulose, gum tragacanth or gelatin; an excipient such 
as starch or lactose, a disintegrating agent such as alginic acid, 
Primogel, or corn starch; a lubricant such as magnesium 
stearate or Sterotes; a glidant such as colloidal silicon diox-
ide; a sweetening agent such as sucrose or saccharin; or a 
flavoring agent such as peppermint, methyl salicylate, or 
orange flavoring. 
For administration by inhalation, the compounds are deliv-
ered in the form of an aerosol spray from pressured container 
or dispenser which contains a suitable propellant, e.g., a gas 
such as carbon dioxide, or a nebulizer. 
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Systemic administration can also be by transmucosal or 
transdermal means. For transmucosal or transdermal admin-
istration, penetrants appropriate to the barrier to be permeated 
are used in the formulation. Such penetrants are generally 
known in the art, and include, for example, for transmucosal 5 
administration, detergents, bile salts, and fusidic acid deriva-
tives. Transmucosal administration can be accomplished 
through the use of nasal sprays or suppositories. For trans-
dermal administration, the active compounds are formulated 





Methods and Materials 
(i) Preparation ofFITC-Labeled, Dephosphorylated Casein 
Casein-Dephosphorylated-casein (Sigma, 3 ml of2 mg/ml 
stock solution) was used in a dialysis cassette (Pierce) placed 
in labeling buffer (0.03 mg/ml FITC, 50 mM sodium borate, 
pH 9.3, 40 mM NaCl) and kept for 48 hat 4° C. in the dark 
with constant stirring. After labeling, the FITC-dephospho-
rylated casein (Dcasein-FITC) was further dialyzed against 
50 mM Tris-HCl, pH 7.5, and 50 mM NaCl to remove any 
The compounds can also be prepared in the form of sup-
positories (e.g., with conventional suppository bases such as 
cocoa butter and other glycerides) or retention enemas for 
rectal delivery. 
15 residual unlabeled FITC. The Dcasein-FITC conjugate was 
recovered from the dialysis cassette and stored at 4 ° C. in the 
dark. In one embodiment, the active compounds are prepared 
with carriers that will protect the compound against rapid 
elimination from the body, such as a controlled release for-
mulation, including implants and microencapsulated delivery 20 
systems. Biodegradable, biocompatible polymers can be 
used, such as ethylene vinyl acetate, polyanhydrides, polyg-
lycolic acid, collagen, polyorthoesters, and polylactic acid. 
Methods for preparation of such formulations will be appar-
ent to those skilled in the art. The materials can also be 25 
(ii) Expression and Purification ofMBP-Omi and MBP-L56 
Proteases-PCR was used to amplify DNA sequences cor-
responding to Omi/HtrA2 (amino acids 134-458) and L56/ 
HtrAl (amino acids 140-480). The PCR products were 
digested with MfeI and XbaI and cloned in the corresponding 
EcoRI and XbaI restriction sites of pMAL-p2X vector (New 
England Biolabs). MBP-Omi-(134-458) and MBP-L56-
(140-480) proteases were expressed in TB! Escherichia coli 
(New England Biolabs) and purified on an amylase binding obtained commercially from Alza Corporation and Nova 
Pharmaceuticals, Inc. Liposomal suspensions (including 
liposomes targeted to infected cells with monoclonal antibod-
ies to viral antigens) can also be used as pharmaceutically 
acceptable carriers. These can be prepared according to meth-
ods known to those skilled in the art, for example, as 
described in U.S. Pat. No. 4,522,811. 
It is especially advantageous to formulate oral or parenteral 
compositions in dosage unit form for ease of administration 
and uniformity of dosage. "Dosage unit form" as used herein 
refers to physically discrete units suited as unitary dosages for 
the subject to be treated; each unit containing a predetermined 
quantity of active compound calculated to produce the 
desired therapeutic effect in association with the required 
pharmaceutical carrier. The specification for the dosage unit 
forms of the invention are dictated by and directly dependent 
on the unique characteristics of the active compound and the 
particular therapeutic effect to be achieved, and the limita-
tions inherent in the art of compounding such an active com-
pound for the treatment of individuals. 
VIII Uses 
In one aspect, the invention can be used to prevent, reduce, 
or ameliorate disorders associated with apoptosis. Examples 
of disorders associated with apoptosis include, but are not 
limited to, ischemia-reperfusion injury (e.g., stroke, myocar-
dial infarction), heart failure-( e.g., loss of myocardiocytes ); 
neurodegeneration disorders-( e.g., Alzheimer's disease, 
Parkinson's disease, Huntington's disease and amytrophic 
lateral sclerosis); inflanmiation; osteoarthritis; human immu-
nodeficiency virus-(loss ofT lymphocytes); bacterial infec-
tion-(apoptosis-inducing virulence proteins are secreted 
into the cytosol ofhost cell. e.g., Shigella species, Salmonella 
species, Yersinia species and Chlamydia species); allograft 
rejection and graft versus host disease; type 1 diabetes; and, 
trauma (spinal-cord injury, brain injury). 
Other embodiments and used of the invention will be 
apparent to those skilled in the art from consideration of the 
specification and practice of the invention disclosed herein. 
All U.S. patents and other references noted herein for what-
ever reason are specifically incorporated by reference. 
affinity column as described by the manufacturer (New 
England Bio labs). The concentration of purified proteases 
was determined using the Bradford assay. 
30 (iii) Expression and Purification of His-Tagged Omi-(134-
458) 
PCR was used to amplify the DNA sequence correspond-
ing to Omi/HtrA2 (Omi-(134-458)). The PCR product was 
cloned in-frame in the bacterial expression vector pET-28 
35 (Novagen). For bacterial expression, BL21 (DE3) (Novagen) 
bacteria were transformed with pET-Omi-(134-458). Single 
colonies were grown overnight in LB medium containing 
kanamycin. The overnight culture (1 ml) was used to inocu-
late I liter of LB medium, and growth was continued at 3 7° C. 
40 until the A600 was -0.8. At this time, 1 mM mist isopropyl-
1-thio-~-D-galactopyranoside was added, and the culture was 
placed in a shaking incubator overnight at 20° C. Bacteria 
were harvested by centrifugation and lysed in a buffer con-
taining 20 mM Tris-HCl, pH 7.5, 500 mM NaCl, 100 µg/ml 
45 lysozyme, and a protease inhibitor mixture (Sigma). The 
bacterial suspension was then sonicated, and the soluble frac-
tion was purified using nickel-nitrilotriacetic acid His-Bind 
resin (Novagen). The purity of the HisOmi-(134-458) protein 
was monitored by SDS-PAGE and Coomassie Blue staining 
50 of the resulting gel. 
(iv) Proteolytic Activity ofOmi Using Dcasein-FITC as Sub-
strate 
Opaque microtiter plates (corning Glass) were used in 
order to minimize background absorbance. A typical assay 
55 included 10 µg of Dcasein-FITC substrate, 2 µg of MBP-
Omi-(134-458) in assay buffer (20 mMNa2HP04 /NaH2P04 , 
pH 7.4, 200 mM NaCl, 5% glycerol) in a final volume of 100 
µ!. Dcasein-FITC conjugate solution (50 µl of a 0.2 µg/µl 
stock solution) was added in each well using a Multidrop 384 
60 multiple dispenser (Lab systems) and incubated in the Wallac 
1420 Victor Multilabel counter at 37° C. for 15 min. After 
this time, 50 µl of MBP-Omi-(134-458) protease ( 40 ng/µl) 
was added to each well. The fluorescence (535 nm) of the 
reactions was recorded every 5 min for a 30-min period. 
65 (v) Combinatorial Library Screening 
A Pharma Library Collection from Nanoscale Cominato-
rial Synthesis Inc., 625 Clyde Ave, Mountain View, Calif. 
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(150 µM), plasmin(5 nM), I-1045 (100 µM)thrombin( 4nM), 
Chromozym PL (150 µM), FVIIa/tissue factor (15 nM/3 nM), 
Chromozym t-PA (500 µM), t-PA (100 nM), I-1140 (200 
µM), u-PA (3 nM), I-1140 (150 µM), activated protein C (5 
94943-2213 was screened for compounds, which may inhibit 
the proteolytic activity ofMBP-Omi-(134-458) in an in vitro 
assay. Each compound, (from a total of 528 compounds) 10 
µM final concentration, was preincubated with 50 µl ofMBP-
Omi-(134-458) (2 µg) for 15 min at 37° C. After this time, 
Dcasein-FITC solution (10 µg) was added, and the change in 
fluorescence was read every 5 min during a 30-min period 
using a 535-nm bandpass filter. The proteolytic activity of 
MBP-Omi-(134-458) was expressed as the percentage inhi-
bition, where 100% refers to the activity in the absence of 
inhibitor (Me2 SO replaced the inhibitor in the assay). 
5 nM), and protein C-activated substrate (100 µM) in a final 
concentration of 5% Me2 SO. All enzymatic assays were car-
ried out at room temperature in 384-well microtiter plates 
(Nurre). Color development due to the release of p-nitroanil-
ide from the chromogenic substrates was monitored continu-
(vi) Activity of Several ucf Analog Compounds Against 
MBP-Omi-(134-458) 
10 ously for 20 min at 405 nm on a Tecan SpectraFluor Plus 
microtiter plate reader (Tecan). fluorescence from the release 
of the coumarin derivative, aminomethylcoumarin, was mea-
sured at excitation 360 nm/emission 465 nm on the same 
reader. The IC50 values were calculated using the GraFit 4 
program (Erithacus Software). 
(ix) Subcellular Localization ofucf-101 
HeLa cells were grown on coverslips using F-12 (Ham's) 
nutrient mixture (Invitrogen) supplemented with 10% fetal 
calf serum (Sigma), 2 mM L-glutamine, 100 units/ml peni-
The assay was performed as described above using 
Dcasein-FITC as substrate. 2 µg ofMBP-Omi-(134-458) was 15 
incubated with various concentrations of ucf-101, ucf-102, 
ucf-103, or ucf-104 for 15 min. After this time 10 µg of 
Dcasein-FITC substrate was added, and the reaction pro-
ceeded for an additional 30 min. The activity ofMBP-Omi-
(134-458) was monitored at 535 nm. 20 cillin, and 100 µg/ml streptomycin (Invitrogen). Different 
concentrations ofucf-101 were added to the cell media, and 
after 2 h cells were washed three times with phosphate-buff-
ered saline and fixed with 4% paraformaldehyde. The cover-
(vii) Determination of IC50 for ucf-101 and ucf-102. 
The IC50 value for each of the two selected inhibitors was 
obtained using His-Omi-(134-458) and the EnzCheck assay 
kit (Molecular Probes) that contains BODIPY FL-casein as a 
generic substrate. Briefly, 35 µl of His-Omi(134-458) (500 25 
nM) diluted in 20 mat Na2HP04 /NaH2P04 , pH 7.4, 200 mM 
NaCl, 5% glycerol was incubated with 5 µl of various con-
centrations of the inhibitors (0.1-1000 µM) in 100% Me2 SO 
(final concentration ofMe2 SO was 10%); 10 µl ofBODIPY-
FL casein (2.5 µM final concentration) diluted in buffer was 30 
added. The assay was carried out using 384-well microtiter 
plates. Fluorescence was monitored continuously for 10 min 
at 3 7° C. on a Tecan SpectraFluor Plus microtiter plate reader 
(Tecan, Crailsheim, Germany) at an excitation wavelength 
485 nm/emission wavelength 530 nm. IC50 values were cal- 35 
culated using the GraFit 4 program (Erithacus Software, 
Middlesex, UK). 
(viii) Activity of ucf-101 Against Various Serine Proteases 
The amount of the inhibitor giving a 50% (IC50) decrease 
of the enzyme activity compared with the control reaction 40 
was estimated for various serine pro-teases. Briefly, 35 µl of 
the indicated enzyme diluted in the corresponding buffer was 
incubated for 10 min with 5 µl of various concentrations of 
inhibitor(0.1-1000 µM) in50% Me2 50, 50% buffer.After this 
time, 10 µl of the corresponding peptidic colorimetric or 45 
fluorogenic substrate diluted in buffer was added. In the case 
of the FVIIa/TF assay, a preincubation of both proteins for 10 
min at room temperature was performed prior to addition of 
the inhibitor to allow complex formation. For this experiment 
the following materials were used: canine FXa, rat FXa, and 50 
rabbit FXa (Enzyme Research Laboratories); trypsin from 
bovine pancreas and human thrombin (Sigma); human plas-
min, human t-PA, human t-PA, and human kallikrein (Cal-
biochem-Novabiochem); human APC and recombinant 
human factor VIIa (American Diagnostica ); and recombinant 55 
tissue factor (Dade Behring). The substrates used are as fol-
lows: spectrozyme FXa fluorogenic (American Diagnostica); 
kallilkrein fluorogenic substrate; protein C-activated sub-
strate (Calbiochem); Chromozym X, Chromozym Pl, and 
Chromozym t-PA (Roche Diagnostics); I-1045, I-1140, and 60 
I-1140 (Bachem). 
The amount of each enzyme and its corresponding sub-
strate used in the assay was canine FXa (2 nM), spectrozyme 
fXa fluorogenic (20 µM), rat FXa (5 nM), spectrozyme fXa 
fluorogenic (25 µM), rabbit FXa (5 nM), spectrozyme FXa 65 
fluorogenic (15 µMr), kallilkrein (5 nM), kallikrein fluoro-
genic substrate (50 µM), trypsin (2.5 nM), Chromozym X 
slips were then placed on glass slides using Fluoromount-G 
solution (Southern Biochemical Association). The subcellu-
lar localization ofucf-101 was monitored using a LSM510 
confocal laser-scarming microscope (Zeiss). 
( x) ucf-101 Inhibits Omi-Induced Caspase-independentApo-
ptosis in Caspase-9-/-) 
Null Fibroblasts-Caspase-9(-/-) cells were transfected 
with eitherpEGFP-Nl vector (Clontech) or M-Omi-GFP that 
encodes a cytoplasmic form of Omi/HtrA2 (Hegde et al 
(2002) J. Biol. Chem. 277, 432-438). Transfected cells were 
kept in medium containing different concentrations of ucf-
101. This medium, including the inhibitor, was replaced every 
12 h. After 36 h, cells were stained with propidium iodide and 
4',6-diamidino-2-phenylindole as described (Hegde et al 
(2002) J. Biol. Chem. 277, 432-438). Normal and apoptotic 
GFP-expressing cells were counted using fluorescence 
microscopy. 
HeLa cells were transfected with mature Omi ( aa134-458), 
Omi-A VPS-GFP and mature Omi where the first Alanine (A) 
was mutated to a Glycine. Omi-GVPS-GFP transfected cells 
were treated with increasing concentration of ucf-101. Over-
expression of mature Omi-GVPS-GFP can induce apoptosis 
only through its ability to function as an active protease 
(caspase-independent pathway). ucf-101 inhibited the pro-
tease activity and apoptosis. 
(xi) Kidney Ischemia/Reperfusion 
Kidney ischemia/reperfusion experiments were performed 
using Balb/c male mice, 20-25 grams, which were anesthe-
tized with sodiumpentobarbital (65 mg/kg) i.p. and undergo 
uninephrectomy of the left kidney followed 24 h later by 
ischemia of the right kidney. This is done by placement of a 
microaneurysm clamp on the renal artery and vein for 30 min 
followed by reperfusion (104). Kidneys were harvested 1, 24, 
and 48 h after reperfusion. 
In bilateral ischemia experiments, ischemia were per-
formed for 30 mM followed by reperfusion (Kelly, et al. 
(1996) J Clin Invest, 97, 1056-63). Kidneys will be harvested 
at the same time points as with nephrectomy/unilateral 
ischemia. Equal amounts of protein extracts from control and 
post-ischemic kidneys will be resolved and analyzed by SDS-
PAGE. The level ofOmi/HtrA2 protein will be determined by 
Western blot analysis using a specific antibody (Hegde, et al. 
(2002) J Biol Chem, 277, 432-8; and Faccio, et al. (2000) J. 
Biol. Chem., 275, 2581-8). 
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(xii) Immunohistochemistry 
Kidneys from control or post-ischemic mice were briefly 
perfused in situ via the heart with PBS (0.9% NaCl in 10 mM 
sodium phosphate buffer, pH 7.4 ), followed by 2% paraform-
aldehyde, 70 mM lysine, and 10 mM sodium periodate (PLP) 5 
and fixed as (Breton, et al. (1998) J Am Soc Nephrol, 9, 
155-66). Kidney slices were immersed in 30% sucrose then 
frozen in liquid nitrogen Semi thin (1 mm). Sections were cut 
from tissue embedded in LX-112 and treated for 2 minutes 
with a mixture of2 g KOH, 5 ml propylene oxide, and 10 ml 10 
methanol to remove the resin. Alternatively, 1 and 5 mm 
cryostat sections were used. Sections will be incubated for 10 
min in PBS containing 1 % BSA to reduce non-specific back-
ground staining, followed by a 2-hour incubation at room 
temperature with a 20-1 drop of specific antibody. After 3x5- 15 
min rinses in PBS, sections were incubated for 1 h with goat 
anti-rabbit IgG coupled to fluorescein isothiocyanate (Cal-
biochem-Behring Corp., San Diego, Calif.), and diluted 1 :30 
for detection of antigenic sites by immunofluorescence 
microscopy. Sections were then rinsed 3x5 min in PBS and 20 
mounted in Gelvatol containing 4% n-propyl gallate (Sigma 
Chemical Co., St. Louis, Mo.) to retard quenching of the 
fluorescence. Photographs of sections were taken on Kodak 
TMAX film using a Nikon FXA photomicroscope with epi-
fluorescence. Some sections were also analyzed using the 25 
ABC-peroxidase procedure. After incubation with the pri-
mary IgG, a biotinylated goat anti-rabbit IgG (Vector Labo-
ratories, Burlinghame, Calif.) were applied to sections for 1 
hour, followed by the ABC reagent (also from Vector Labo-
ratories) for a further 1 hour. Peroxidase was revealed with 30 
diaminobenzidine and H20 2 , and the sections dehydrated in 
ethanol and mounted in Permount (Fisher Scientific Co.). 
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For control monolayers, not subject to ATP depletion, dex-
trose (10 mM) will be added to the DMEM medium. ATP 
depletion of varying severity was induced using 2 mM anti-
mycin (Sigma) or 5 mM 2-deoxyglucose (DOG) (Sigma) 
with and without varying concentrations of dextrose. Anti-
mycin alone causes the most severe ATP depletion and 
induces cell death by necrosis. DOG alone causes intermedi-
ate ATP depletion and induces apoptotic cell death (95). Six 
different metabolic conditions were used: 1) antimycin alone, 
2) antimycin +0.25 mM dextrose, 3) antimycin+l mM dex-
trose, 4) DOG alone, 5) DOG+4 mM dextrose, and 6) DOG+ 
10 mM dextrose. 
(xvii) Cisplatin-InducedApoptosis. 
MPT cells was plated in serum-free medium [1: 1 mixture 
of DMEM and Ham's F-12] (GIBCO) containing 2 µM 
glutamine, 50 U/ml penicillin, 50 mg/ml streptomicyn 
(GIBCO), 15 mM HEPES, 5 mg/ml transferring, 5 mg/ml 
insulin and 50 nM hydrocortisone (Sigma). Medium was 
replaced every 2 days and the cells were used 6 to 8 days later. 
The MPT cells were incubated with various concentrations 
(10, 20, 50, and 100 mM) of cisplatin or vehicle (methylfor-
mamide) for 48 hours and analyzed by Flow Cytometry, or 
extracts were prepared for Western blot analysis. 
(xviii) Induction ofApoptosis onHK-2 Cell Line Using H2 0 2 
HK-2 cells were cultured in DMEM medium containing 2 
mM glutamine, 50 U/ml penicillin, 50 µg/ml streptomycin 
(GIBCO), 15 mM HEPES, 5 mg/ml apotransferrin, 5 mg/ml 
insulin and 50 nM hydrocortisone. Approximately 90% con-
fluent cells were treated with various concentrations ofH2 0 2 
(10, 20, 50, 100 µM) for 18 hours. Whole cell extracts were 
prepared and analyzed by Western blot analysis using Omi/ 
HtrA2 antibodies. (xiii) Cell Culture 
HK-2 cells were grown in DMEM/HamF12 media supple- (xix) Use of siRNAs to Suppress Omi/HtrA2 Expression in 
mented with 10% FCS, hydrocortisone (0.4 µg/ml), insulin, 35 Proximal Tubular Cells. 
transferring and sodium selenite (all used at a final cone. 5 The pSuppressor2 vector available from Imgenex (San 
µg/ml). LLC-PKl cells were grown in DMEM plus 10% FCS Diego, Calif., Paul, et al. (2002) Nat Biotechnol, 20, 505-8) 
and MDCK in MEM plus 10% FCS. was used to stably express the small interfering RNA (siRNA) 
(xiv) Isolation of Mouse Primary Kidney Proximal Tubular that is homologous to Omi/HtrA2 mRNA sequence. 
(MPT) Cells 40 A double stranded ( ds) oligo with the following sequence was 
MPT cells were isolated from collagenase-digested frag- used: 
ments derived from the cortices of kidneys ofC57BL6 mice 
as described (Sheridan, et al. (l993)AmJ Physiol, 265, F342-
d h" 1 ( ) h l ) (SEQ ID NO, 2) 50; an Kras rnn, et a· 1994 Am JP ysio' 266, F21-30 · 5' -TCGAATTCGCTGGGGGAGGAGACagtactGTCTCCTcccccAGCGAA 
MPT cells were grown in serum-free medium (1: 1 mixture of 45 TTTTT- 3 , 
Dulbecco's modified Eagle's medium (DMEM) and Ham's 
F-12) containing 15 mM Hepes, 5 µg/ml insulin, 50 nM 
hydrocortisone, 5 µg/ml apotransferrin, 50 µg/ml penicillin, 
and 50 µg/ml streptomycin. The cells were used between the 
5th and 10th day after culture. 
(xv) Confocal Microscopy 
50 
Mouse proximal tubular cells were grown for 6 days on 
microscope cover slides. Adherent cells were washed in PBS, 
fixed in 4% paraformaldehyde and made permeable using 
ice-cold acetone. Non-specific binding was blocked with 2% 55 
BSA in PBS and, subsequently, cells were stained using a 
rabbit anti-Omi and a mouse anti-gp330 antibodies at room 
temperature for 2 hours. After three washes with PBS, sec-
ondary antibodies cy3 conjugated anti-rabbit and Oregon-
green conjugated anti-mouse was added for one hour. Finally, 60 
the cover slips were washed and placed on microscope slides 
using Fluoromount-G as the mounting solution. Slides were 
observed using a LSM510 confocal laser scanning micro-
scope (Zeiss). 
(xvi) ATP Depletion ofMPT Cells Using Chemical Anoxia 65 
MPT cells were incubated in dextrose-free DMEM at 37° 
C. in a humidified atmosphere containing 5% C02 -95% air. 
(SEQ ID NO, 3) 
3'-TAAGCGACCCCCTCCTCTGtcatgaCAGAGGAGGGGGTCGCTTAAAA 
ATCTAG-5' 
This double stranded oligo encodes 19 base pairs repre-
senting sequence 51-70 nucleotides downstream of the ini-
tiation of translation of Omi/HtrA2. The sense and antisense 
sequence is separated by a stem loop of 6 nucleotides that 
encodes the Sea I restriction site used for easy identification 
of the insert. The double stranded oligo was cloned into the 
corresponding sites of the pSupressor2 vector and bacterial 
clones was screened by isolating plasmid DNA followed by 
restriction digest with Sea I restriction enzyme. Positive 
clones will have their plasmid DNA sequenced as described 
by Faccio, et al. ((2000) J. Biol. Chem., 275, 2581-8). The 
pSuppresor/Omi clone was used to transfect HK-2 cells. The 
vector has the NeoR gene and permanent cell lines can be 
made using G418 (Invitrogen) in the culture medium. The 
effectiveness of this siRNA to suppress expression of the 
Omi/HtrA2 will be monitored by Western blot analysis using 
total cell extracts and anti-Omi antibodies. As a control, cell 
lines were made using the pSuppressor2 vector alone. 
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(xx) Cell Viability Assay 
24 
Bioscience) and stained with PE-conjugated annexin V 
according to BD Bioscience protocol. Analysis of GFP and 
annexin V positive cells will be performed on a FACS Vantage 
Flow Cytometer (Becton Dickinson). 
Example 2 
Activity of Omi Protease Against Dcasein-FITC 
This example demonstrates the activity of Omi protease 
against Dcasein-FITC. As no physiological substrates for 
Omi protease are known, ~-casein was used as a generic 
substrate in in vitro assays to monitor the protease activity of 
Omi. For high throughput screening, a new assay was devel-
oped that uses a mixture of a-casein, ~-casein, and dephos-
phorylated casein (Dcasein) coupled to FITC, as a substrate, 
The use of Dcasein-FITC increases the fluorescence during 
The viability of cells was monitored using the MTT assay 
(Buttke, et al. (1993) J Immunol Methods, 157, 233-40; and 
Mossman, (1983) Environ Health Perspect, 53, 155-61 ). The 
assay is based on the ability of the mitochondria of viable 5 
cells to cleave the tetrazolium rings of the pale yellow MTT 
dye to form dark blue formazan crystals. The amount of 
formazan product produced is directly proportional to the 
number of viable cells present in the culture well. After 
removal of the medium, MTT (1 µg/ml) is added to each well 10 
and incubated at 37° C. for 4 hours. The formazan crystals 
formed by viable cells are then dissolved by adding 10% 
SDS/0.01 N HCl to each well and incubating overnight. The 
absorbance of aliquots from each well will be read by 1420 
Multilabel counter Victor2 (Wallac) plate reader with a test 15 
wavelength of 570 nm and a reference wavelength of 650 nm. 
Percent viability will be expressed as the absorbance of ATP-
depleted cells with the ucf-101 inhibitor/absorbance of ATP-
depleted cells without the inhibitor, where DMSO is added 
instead. 20 the reaction with less fluctuation and lower background (data 
not shown). A typical assay uses 10 µg of Dcasein-FITC and 
2 µg MBP-Omi-(134-458) in 100 µl of reaction buffer (20 
mM sodium phosphate buffer, pH 7 .5, 200 mMNaCl, and 5% 
(xxi) Transfection of Mammalian Cells 
60% confluent cells were transfected using the Lipo-
fectamine Plus Reagent according to the instructions pro-
vided by the manufacturer (Life Technologies). 
(xxi) Quantitative Real-Time PCR Analysis of Omi/HtrA2 25 
mRNA. 
glycerol) at 37° C. for 30 min. 
The results show that there was a rapid increase in fluores-
cence for the first 20 min followed by a slower increase forthe 
remaining 10 min of the assay. Various concentrations of 
substrate, Dcasein-FITC, as well as MBP-Omi-(134-458) 
Total RNA was isolated from MPT cells using the QIAgen 
RNeasy kit following manufacturer's instructions. 2 µg of 
total RNA was transcribed into cDNA using the Omniscript 
reverse transcriptase (QIAgen). Real-Time PCR was per-
formed with AmpliTaq Gold polymerase in a iCycler real-
time PCR thermocycler (BioRad) and the Sy Br Green detec-
tion protocol as per the manufacturer's instructions. Briefly, 
30 were used for kinetic studies. 
12 ng of total cDNA, 50 nM of each primer and lx SyBr 
Green mix was used in a total volume of 25 µ!. The primer 35 
sequences for murine Omi/HtrA2 are: Sense 
5'-GCGGGGCGGGGTGCAAAC-3' (SEQ ID NO: 4) and 
antisense 5'-GACAGCCAGCACCGTGG-3' (SEQ ID NO: 
5). Murine b-actin primers: sense 5'-TTCGTTGCCGGTC-
CACA-3' (SEQ ID NO: 6) and antisense 5'-ACCAGCG- 40 
CAGCGATATCG-3' (SEQ ID NO: 7). Samples were read in 
triplicate and normalized for expression of ~-actin RNA. 
(xxii) Western Blot Analysis 
For Western blot analysis, cells were harvested 24 hours 
after transfection, washed and lysed using a Triton X-100 45 
based buffer (1% Triton X-100, 10% Glycerol, 150 mM 
NaCl, 20 mM Tris-HCl pH 7.5, 2 mM EDTA) containing a 
protease inhibitors cocktail (Roche). Approximately 30 µg of 
the whole cell extracts were re-suspended in SDS-sample 
buffer and boiled for 3 minutes. The samples were resolved by 50 
SDS-PAGE and electro-transferred onto PVDF membranes 
(Pall Corporation) using a Semi-Dry Transfer Blot (Bio-Rad). 
Non-specific binding was blocked using 2% nonfat dry milk 
in TBST to saturate the membrane. The blot was then incu-
bated with an anti-GFP monoclonal antibody (Santa Cruz 55 
Biotechnology), 1:700 dilution followed by a secondary 
horseradish peroxidase-conjugated goat anti-mouse antibody 
(Jackson ImmunoResearch), 1: 15000 dilution, and visual-
ized by chemiluminescence (ECL) using a SuperSignal West 
Pico substrate (Pierce). 60 
(xxiii) Flow Cytometry 
Cells were grown on 6 well plates using appropriate media. 
60% confluent cells were transfected with various constructs 
using Lipofectamine Plus Reagent according to the instruc-
tions provided by the manufacturer (Life Technologies). The 65 
transfected cells were detached 48 hours later, washed twice 
with ice-cold PBS, resuspended in 1 x binding buffer (BD 
Example 3 
Combinatorial Library Screening 
By using an in vitro high throughput assay system, a com-
binatorial library of synthetic compounds (Nanosyn) was 
screened. This collection represented compounds that had 
commonly accepted pharmaceutical hit structures with pos-
sible pharmacological properties. The assay was performed 
in multiple 96-well plates. The inhibition activity of each 
compound was expressed as the percentage of relative fluo-
rescence change (decrease) compared with the control (no 
compound). The final concentration of each compound tested 
was 10 µM. Fifty two compounds showed more than a 20% 
inhibition of MBP-Omi-(134-458) activity in the initial 
screening, but only one compound (ucf-101) showed greater 
than a 50% inhibition at the concentration tested after two 
rounds of screening and selection (Table III). 
TABLE III 
Screening for inhibitors oftbe proteolytic activity ofOmi 
A combinatorial library of 528 selected compounds was used in a 
high tbroughout screening for potential inhibitors oftbe proteolytic 
activity ofOmi. Several compmmds had weak activity against Omi, 
but after two rounds of selection only one chemical showed 
substantial and reproducible inhibition against Omi in the assay used. 
% inhibition 1st screening 2 screening 
0 26 
1-19 468 47 
20-39 52 
40-59 2 
Total 528 75 
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Example 4 
Inhibition of the Proteolytic Activity of 
MBP-Omi-(134-458) Using ucf-101 and Various 
Analogs 
Several analogs ofucf-101 were obtained, and the chemi-
26 
Example 6 
Comparison of the Proteolytic Activities of His-Omi 
(134-458) and His-L56-(156-480) 
Proteins-OmiHtrA2 and L56/HtrA1 are members of the 
same family of mammalian serine proteases with extensive 
homology in their catalytic domains (Faceio et al. (2000) J. 
Biol. Chem. 275, 2581-2588). Bacterially made His-Omi-
10 (134-458) and His-L56-(140-480) was used to investigate 
whether ucf-101 was able to inhibit the activity ofHis-L56-
(140-480) in a similar manner. FIG. 9 shows the inhibition of 
the proteolytic activity of MBP-Omi-(134-458) and MBP-
L56-(140-480) by ucf-101. The assay was performed with 10 
cal structures are shown in FIGS.1-4. The activity of these ucf 
analogs was tested using MBP-Omi-(134-458) in the same in 
vitro assay system. FIG. 7 shows the inhibition ofMBP-Omi-
(134-458) by ucf-101 and several other ucf analogs. The 
assay was performed with 10 µg ofDcasein-FITC incubated 
with 2 µg ofMBP-Omi-(134-458) in the presence of various 
concentrations of ucf-101 and three analogs, ucf-102, ucf-
103, and ucf-104. •, ucf-101; .._, ucf-104; e, ucf-103; +, 
ucf-102. All three analogs inhibited the proteolytic activity of 
MBP-Omi-(134-458) but to a lesser extent than ucf-101. ucf-
104 (20 µM) inhibited 58% MBP-Omi-(134-458) activity, 
whereas the same concentration of ucf-101 inhibited more 
than 78% MBP-Omi-(134-458) activity. When MBP-Omi-
(134-458) was preincubated with various concentrations of 
ucf-101, -102, -103, and -104 at 37° C for longer periods ( 40 
mill or 1 h) inhibition was reduced, indicating the inhibitors 
did not irreversibly bind the enzyme (results not shown). 25 
MBP-Omi-(134-458) was also incubated with various 
amounts ofDcasein-FITC in the presence of 10 µM ucf-101. 
The rate of the reaction decreased by 50% when the concen-
tration of the substrate was doubled and even reached the rate 
15 µg ofFITC-Dcasein and 2 µg ofMBP-Omi-(134-458) (MBP-
Omi) or MBP-L56-(140-480) (MBP-L56) in the presence of 
various concentrations ofucf-101. The increase in fluores-
cence for the initial 20 min was used for comparing the 
activities of MBP-Omi-(134-458) or MBP-L56-(140-
20 480). +, MBP-Omi; • MBP-L56. 
of the control reaction at higher concentrations of Dcasein- 30 
FITC (results not shown). These results suggest ucf-101 is a 
competitive inhibitor of Omi protease. 
Example 5 
Assay ofHis-Omi-(134-458) Activity Using 
Unlabeled ~-Casein and SDS PAGE Analysis 
35 
The inhibitory effect ofucf-101 on the activity ofHis-Omi-
(134-458) was monitored by incubating inhibitor and enzyme 40 
together for 10 min at room temperature prior to the addition 
of ~-casein as a generic substrate. An in vitro assay of the 
proteolytic activity ofHis-Omi-(134-458) in the presence of 
different concentrations of ucf-101 was performed, and the 
results shown in FIG. 8. The assay was performed at 37° C., 45 
and after the indicated time points the reactions were resolved 
on SDS-PAGE and the gel stained with Coomassie Blue. Omi 
(200 ng) was incubated with 5 µg of~-casein substrate in a 20 
µl reaction volume for 30 min at 37° C. The ucf-101 com-
pound was preincubated with His-Omi-(134-458) (His-Omi) 50 
protease for 10 min at room temperature prior to the addition 
of ~-casein substrate. (Lane 1, ~-casein control; lane 2, His-
Omi+~-casein, digested for 15 min; lane 3, His-Omi+~­
casein, digested for 30 min; lane 4, His-Omi+lOO µM ucf-
101+~-casein; lane 5, His-Omi+80 µM ucf-101+~-casein; 55 
lane 6, His-Omi+50 µM ucf-101 +~-casein; lane 7, His-Omi+ 
30 µM ucf-101+~-casein; lane 8, His-Omi+20 µM ucf-101+ 
~-casein; lane 9, His-Omi+lO µM ucf-101+~-casein; and lane 
10, prestained molecular weight marker.) 
FIG. 8 shows that bacterially made His-Omi-(134-458) 60 
had substantial activity against ~-casein, and after 30 min 
total degradation of the substrate occurred. ucf-101 inhibited 
His-Omi-(134-458) activity in a concentration-dependent 
manner (lanes 4-9) when assayed for 30 min with 200 ng of 
His-Omi-(134-458) and 5 µg of ~-casein. ucf-101 (80 µM) 65 
was able to inhibit completely the activity of 200 ng of His-
Omi-(134-458) (lane 5). 
FIG. 9 shows ucf-101 is an effective inhibitorof the activity 
of His-L56-(140-480) but to a lesser extent than His-Omi-
(134-458). 
Example 7 
IC50 ofucf-101 Against Various Serine Proteases 
The enzymatic activity of His-Omi and the determination 
of the IC50 for ucf-101 and ucf-102 were performed as 
described in Example 1 (vii). These values are shown in Table 
IV. ucf-101 hadanIC50 of9.5 µM, and ucf-102 hadanIC50 of 
45.9 µM. 
TABLE IV 




1C50 in µM 
9.5 
45.9 
The value is the average from three independent experiments. 
The specificity of ucf-101 was determined using several 
unrelated serine proteases. Their susceptibility to inhibition 
by ucf-101 was tested. The IC50 values for ucf-101 inhibitor 
from these experiments are shown in Table IV. These results 
suggest ucf-101 has very high specificity for the Omi pro-
tease. 
TABLE IV 
IC50 values ofucf-101 on various protease 
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TABLE IV-continued 
IC 5a values ofucf-101 on various protease 









The two IC50 values are derived from two independent experiments. 
The two IC50 values are derived from two independent experiments. 
Example 8 
Intracellular Localization of ucf-101 
28 
similar to Smac/DIABLO, another mitochondrial protein that 
also binds to XIAP (Du et al. (2000) Cell 102, 33-42; and 
Verhagen et al., (2000) Cell I 02, 43-53 ). This interaction with 
XIAP is mediated via an AVPS motif that is exposed at the 
5 amino terminus of mature Omi protein after processing (Su-
zuki et al. Supra, Hegde et al. Supra). 
Omi/HtrA2 is also able to induce apoptosis in a caspase-
independent manner that exclusively relies on its ability to 
function as a protease (Suzuki et al. (2001) Mal. Cell. 8, 
10 613-621; Hegde et al. Supra; Martins et al. (2002) J. Biol. 
Chem. 277, 439-444; Verhagen et al. Supra; and van Loo et al. 
(2002) Cell Death Differ. 9, 20-26). This caspase-independent 
pathway is not well understood; its contribution to overall cell 
death is not known, and the role of Omi as a protease in this 
15 pathway is not clear. Because the caspase-independent path-
way relies on the ability of Omi/HtrA2 to function as a pro-
tease, it suggests that proteolytic cleavage of specific proteins 
is involved. This cleavage might inactivate and remove apo-
ptotic inhibitors, or it may activate precursor proteins whose 
20 function might be necessary for caspase-independent cell 
death. To investigate the potential use of ucf-101 inhibitor in in 
vivo experiments, the ability of the inhibitor to enter mam-
malian cells was tested. ucf-101 has natural fluorescence at 
543 nm that was used to detect the presence of the compound. 
HeLa cells were treated with different concentrations ofucf- 25 
In order to investigate the contribution of the proteolytic 
activity of Omi to its overall pro-apoptotic function, specific 
inhibitor(s) of its activity were screened. One such specific 
inhibitor was identified and called ucf-101. This heterocycic 
compound was able to inhibit the proteolytic activity of Omi 
in vitro in a very specific and reversible manner. The speci-
ficity ofucf-101 was tested against a panel of several unre-
lated serine proteases, and no significant activity was 
101 and observed by confocal microscopy. Intense red fluo-
rescence, due to the presence ofucf-101, was observed in the 
cytoplasm of the treated cells. 
The cytoplasmic localization of ucf-101 was examined 
when subconfluent HeLa cells were treated with 50 (A), 40 
(B), and 20 µM (C) ucf-101 and were observed using a con-
focal microscope. A-C show cytoplasmic red staining due to 
the presence of ucf-101, indicating cells are permeable to this 
chemical. No staining was seen when Me2 SO alone was used. 
D (results not shown) 
Example 9 
ucf-101 Can Inhibit Omi-Induced 
Caspase-Independent Apoptosis 
The inhibition of Omi-induced caspase independent cell 
death by ucf-101 was examined. Mouse embryo caspase-
9 (-/-/-)null fibroblasts (Hakem et al. (1998) Cell 94; 339-
352) were transiently transfected with pEGFP-Nl (control) 
or Omi-GFP (Hegde et al, Supra). The transfected cells were 
kept in medium containing different concentrations of ucf-
101. The percentage of apoptotic cells in the transfected 
population was determined after 36 has described by Hakem 
et al. (1998), Supra. 
Cytoplasmic expression of M-Omi-GFP induced apopto-
sis in -70% of the transfected cells. When cells were treated 
with increasing concentrations ofucf-101, it was found that 
increasing the concentration of inhibitor up to 10 µM gradu-
ally reduced Omi-induced apoptosis up to 40%. ucf-101 had 
no effect on the control (vector alone) transfected cells. When 
the concentration of the ucf-101 increased to 25 µM, the 
anti-apoptotic activity of the inhibitor was compromised due 
to a cytotoxic side effect that caused apoptosis both in the 
M-Omi-GFP, as well as control transfected cells (FIG. 10). 
30 detected. When L56/HtrA1 was used in the same assay, ucf-
101 showed specific inhibition against this protease. L56/ 
HtrAl belongs to the same family of proteases as Omi, and 
they both share extensive homology throughout their respec-
tive catalytic domains (Faceio et al. (2000) J. Biol. Chem. 27 5, 
35 2581-2588). The normal functionofL56/HtrA2 is not known, 
and unlike Omi that localizes to mitochondria, L56 is secreted 
(Ru et al. (1998) J. Biol. Chem. 273, 34406-34412). The 
natural fluorescence ofucf-101 was used to monitor its ability 
to enter mammalian cells. This property is necessary for 
40 ucf-101 to be useful for in vivo experiments designed to test 
inhibition of Omi that is intracellular. 
To test the ability of ucf-101 to inhibit the proteolytic 
activity of Omi in vivo, an assay was used where transient 
overexpression of a cytoplasmic form of Omi induces 
45 caspase-independent cell death (Hedge et al, supra). The cells 
used in this assay were caspase-9 (-/-)null mouse embryonic 
fibroblasts (Hakem et al. supra)) in which over-expression of 
a cytoplasmic form ofOmi can induce the caspase-indepen-
dent pathway of apoptosis. This form of cell death caused by 
50 Omi relies entirely on its ability to function as a protease. 
Therefore, ifucf-101 blocks the activity ofOmi, it will inter-
fere with apoptosis of the caspase-9 (-/-)mouse embryonic 
fibroblasts. When these fibroblasts were transfected with the 
vector encoding the cytoplasmic Omi and treated with ucf-
55 101, apoptosis was dramatically reduced. 
60 
Example 10 
Omi/HtrA2 is Predominantly Expressed in the 
Proximal Kidney Tubules 
Collectively, these results demonstrate that Omi/HtrA2 is a 
mitochondrial serine protease that is released to the cyto-
plasm upon induction of apoptosis. In the cytoplasm, Omi 
binds to XIAP and relieves its inhibition of caspase-9 (Suzuki 
eta!. (2001)Mol. Cell. 8, 613-621; Hegde et al. (2002)J. Biol. 65 
Chem. 277, 432-438; and Verhagen et al., (2002) J. Biol. 
Chem. 277, 445-454). In this respect, Omi acts in a manner 
To determine the expression profile of Omi/HtrA2 in kid-
ney cells, immunocytochemical staining for Omi/HtrA2 was 
performed as described (Faccio et al. (2000). J. Biol. Chem., 
275, 2581-8 and Park, et al (2002) J Biol Chem, 277, 2040-
9)). Human kidney sections were obtained from Biochain 
Institute Inc. (Hayward, Calif.) and mouse sections were pre-
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pared as previously described (Faccio et al (2000 Supra). 
Omi/HtrA2 antiserum was raised against bacterially made 
His-tagged Omi/HtrA2 protein (residues 134-458) and affin-
ity purified (Hegde, et al (2002) Supra). Proximal tubules 
were identified by apical staining with anti-gp330 (also 5 
known as megalin) (green) (Kerjaschki, et al (1982) PNAS, 
79, 5557-81). Omi/HtrA2 protein expression was indicated 
by red staining; when both images are merged there was 
extensive co-localization of gp330 and Omi/HtrA2. Both 




HtrA2 (red) (1 ). The same MPT cells stained with anti-gp330 
antibodies (green) (2) and Nomarsky images of the MPT cells 
were also produced. The results show that Omi/HtrA2 protein 
and distinct punctate perinuclear staining in normal MPT 
cells and co-localizes with mitochondrial staining. After 
induction of apoptosis MPT cells show more intense Omi/ 
HtrA2 staining that is more diffuse and extends throughout 
the cell. 
Example 14 
The Protein Level of Omi/HtrA2 Increases in MPT 
Cells Induced with Various Apoptotic Stimuli 
Expression of Omi/HtrA2 is Upregulated After 
Ischemia/Reperfusion 
15 To investigate the protein level of Omi/HtrA2, MPT cells 
were isolated and exposed to different concentrations of cis-
platin for 48 hours, or they were treated with 2 µM antimycin 
for different time periods. Approximately 5 µg protein of total 
cell extract was resolved by SDS-PAGE, transferred to a 
To show that Omi/Htra2 was upregulated after ischemia/ 
reperfusion, Balb/c male mice underwent uninephrectomy of 
the left kidney and, 24 hours later, ischemia was induced on 
the right kidney for 30 min followed by reperfusion (Park, et 
al. (2002) J Biol. Chem., 277, 2040-9). Kidneys were har-
vested 90 min and 24 hours after reperfusion and processed as 
described in Example 1 (xi). Sections of mouse kidneys 
showed a substantial increase in the intensity of Omi/HtrA2 
staining 90 min and 24 hours after ischemia/reperfusion as 
compared with sham operated kidneys withAnti-Omi having 
a red fluorescence and anti-gp330 having a green fluores-
cence (data not shown). 
20 PVDF membrane and probed using the anti-Omi antibodies 
as described in Example 1. 
Western blot analysis showed up-regulation of Omi/HtrA2 
protein following inductionofapoptosis (See FIG. lla ). Both 
cisplatin and antimycin treatment induced expression ofOmi/ 
25 HtrA2 protein in MPT cells. 
A Western blot analysis of Omi/HtrA2 protein in HK-2 
(human proximal tubular epithelial cell line) cells after induc-
tion of apoptosis using the indicated concentrations ofH2 0 2 
for 18 hours is shown in FIG. llb. The results show that the 
Example 12 
Expression of Omi/HtrA2 Protein in Proximal 
Tubule (MPT) Cells 
30 basal protein level ofOmi/HtrA2 is higher in HK-2 cells than 
in primary MPT cells. In the HK-2 cell line, there is also 
substantial increase in the level of the Omi/HtrA2 protein 
after induction of apoptosis with H20 2 . 
To investigate the expression of Omi/HtrA2 protein in 
proximal tubule (MPT) cells, MPT cells were isolated from 
the kidneys of 4-5 week old mice as described in the Example 
35 
1. Confocal microscope images of two representative popu-
lations of MPT cells were stained with anti-Omi (red) and 40 
anti-gp330 (green). Mouse proximal tubular cells were grown 
for 6 days on microscope cover glass. Adherent cells were 
stained using a rabbit anti-Omi and a mouse anti-gp330 at 
room temperature for 2 hours. Secondary antibodies used 
were: cy3 conjugated anti-rabbit and Oregon-green conju- 45 
gated anti-mouse. Images were obtained using a LSM510 
confocal laser scanning microscope (Zeiss). MPT cells were 
stained with anti-Omi/HtrA2 (Al and Bl). The same MPT 
cells were stained with anti-gp330 antibodies (green) (A2 and 
B2). Merged images of 1 and 2 (A3 and B3). Nomarsky 50 
images (A4 and B4). The results show that all MPT cells 
identified by staining with anti-gp330 also stained positive 
with anti-Omi/HtrA2 (data not shown). 
Example 15 
Ucf-101 Protects MPT Cells from Cisplatin-Induced 
Apoptosis 
This example describes the protective effects of an inhibi-
torofapoptosis, Ucf-101 oncisplatin-induced apoptosis. Cis-
platin used at low doses can also induce apoptosis in RTECs 
whereas high doses induce necrosis (Lieberthal, et al. (1996) 
Am J Physiol, 270, F700-8; and Lau, et al. (1999) Kidney Int, 
56, 1295-8). Early animal studies have shown apoptosis to 
occur in rat kidney cortexes 12 hours after ischemia/reperfu-
sion (Schumer, et al. (1992) Am J Pathol, 140, 831-8). More 
studies have described apoptosis to occur in ischemia/reper-
fusion injury to the kidney (Nakajima, et al. (1996) Am J 
Physiol, 271, F846-53; Yin, et al. (1997) J Biol Chem, 272, 
19943-50; Nogae, et al. (1998) J Am Soc Nephrol, 9, 620-31; 
and Raafat, et al. (1997) Shock, 8, 186-92). Ucf-101 was 
isolated for its ability to inhibit the proteolytic activity of 
Omi/HtrA2 in vitro (Cilenti, et al. (2003) J Biol Chem, 278, 
Example 13 55 11489-94). 
Subcellular Localization of Omi/HtrA2 in Normal 
and Apoptotic MPT Cells 
The subcellular localization of Omi/HtrA2 in normal and 60 
The ability ofucf-101 to passively enter mammalian cells 
makes it possible to be used for in vivo studies. It was hypoth-
esized that ifOmi/HtrA2 through its proteolytic activity plays 
a role in tubular cell death following renal injury, ucf-101 
inhibitor will have a protective anti-apoptotic function in the 
same system. Previous studies have shown that treatment of apoptotic MPT cells was investigated by as described in 
Example 1. Confocal microscope images of normal or apop-
totic MPT cells stained with anti-Omi (red) and MitoTracker 
(green) (data not shown). Apoptosis was induced using 2 µM 
Antimycin for 1 hour. Omi antibody staining was done as 
described in Example 1. 50 nM of MitoTracker dye was 
added for 20 minutes. MPT cells stained with anti-Omi/ 
MPT cells with cisplatin caused increased expression of p53, 
and this induction of p53 was necessary and essential for 
cisplatin-induced apoptosis (Cummings, et al. (2002) J Phar-
65 macol Exp Ther, 302, 8-17; and Xiao, et al. (2003) J Toxicol 
Environ Health A, 66, 469-79). Furthermore, a recent report 
showed that Omi/HtrA2 expression is directly regulated by 
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p53 at least in HeLa cells (Jin, et al. (2003) Genes Dev, 17, 
359-67). It was therefore hypothesized that Omi/HtrA2 was 
involved in the cisplatin-induced apoptosis as a downstream 
effector of p53 and ucf-101 was tested as an inhibitor of in 
cisplatin-induced apoptosis. 
FIG. 12 shows that ucf-101 blocks cisplatin-induced apo-
ptosis in MPT cells. MPT cells were treated with either 20 µM 
or 50 µM ucf-101 for 20 minutes. After this time, apoptosis 
was induced with different concentrations of cisplatin for 6 
hours. Cells were detached, washed with PBS and stained 
withannexin Vaccordingto BD Biosciences protocol.Analy-
sis of annexin V positive cells was performed on a FACS 
Vantage Flow Cytometer (Becton Dickinson). Results shown 
are the average values from three independent experiments. 
The data shows that ucf 101 reduces apoptosis in a dose-
dependent manner in cisplatin induced apoptotic cells. 
Collectively, the data shows that Omi/HtrA2 is expressed 
in the kidney proximal tubules, an area highly susceptible to 
injury and cell death. Furthermore, the protein level of Omi/ 
HtrA2 dramatically increased after kidney ischemia/reperfu-
sion in MPT cells treated with antimycin or cisplatin as well 
as in HK-2 cells treated with H20 2 . Finally, ucf-101, a spe-
cific inhibitor of the proteolytic activity ofOmi/HtrA2, pro-
tects MPT cells from cisplatin-induced apoptosis. These 
results suggest that Omi/HtrA2 plays an important role in 
injury/apoptosis that occurs in proximal tubule cells follow-
ing ischemic or chemical insult. 
Example 16 
The Function ofD-Omi 
This example investigates the roles of D-Omi, a kidney-
specific, alternatively spliced form of Omi/HtrA2. Omi/ 
HtrA2 is expressed ubiquitously but recently an alternatively 
spliced form (D-Omi) has been isolated by this group, and is 
found predominantly in the kidney and to a lesser extent in the 
32 
protein (GFP). After transfection into mammalian cells, their 
localization, processing and ability to induce apoptosis was 
monitored. 
FIG.14 shows the expression and processing of the various 
5 GFP-fusion proteins. Equal amounts of whole-cell lysates 
obtained 24 hours post-transfection were subjected to SDS-
PAGE followed by immunoblotting using anti-GFP antibod-
ies. Lanes 1-7, cell lysates prepared from HeLa cells trans-
fected with the corresponding construct: Omi-GFP, Omi-S/ 
10 A-GFP, Omi-L56-GFP, Omi-L56-S/A-GFP, Omi-li.7-GFP, 
Omi-li.3-GFP, and D-Omi-GFP 
FIG. 15 shows the results from an apoptotic assay of vari-
ous GFP-fusion proteins. 293T cells were transfected using 
the same constructs shown in FIG. 13. 48 hours later, trans-
15 fected cells were detached and stained with PE-conjugated 
annexin V. The percentage of GFP positive cells that were also 
annexin V positive is shown. The number represents the aver-
age of four independent experiments. 
This data shows that D-Omi, due to its inability to function 
20 as a protease, is not processed to the mature form of the 
protein. This causes the amino terminal part ( aa 1-133) that is 
usually removed in the mature Omi/HtrA2 protein to remain 
attached on D-Omi. As a result, D-Omi is unable to induce 
apoptosis in a caspase-dependent manner since it can not 
25 expose the AVPS internal sequence motif necessary for bind-
ing to the inhibitor of apoptosis proteins (IAPs ). Furthermore, 
since it is an inactive protease, it cannot induce apoptosis in a 
caspase-independent pathway. The results showed that 
D-Omi still retains some residual activity and it is able to 
30 induce apoptosis in 15% oftransfected 293T cells, which is 
approximately half the apoptotic potential of mature Omi/ 
HtrA2. The function ofD-Omi is not known; it could act as a 
dominant negative, blocking the activity of Omi/HtrA2, or it 
could induce apoptosis in a new, independent mechanism. 
35 
Example 17 
Kidney-Specific Substrates for Omi/HtrA2 Protease 
colon and thyroid (Faccio, et al. (2000) Genomics, 68, 343-7). 40 This example describes the identification of substrates for 
D-Omi lacks the amino acid sequence encoded by exons 3 Omi/HtrA2 protease. Omi/HtrA2 is an active serine protease. 
and 7 that affects both its catalytic domain as well as the PDZ This activity is necessary for processing the precursor protein 
domain. The function of D-Omi is not known. Its restricted to its mature form. This processing exposes an internal AVPS 
tissue-specific expression might suggest a specific role in the motif at the amino terminus which is used to bind the inhibitor 
organs where it is found. 45 of apoptosis proteins (IAP) and induce caspase-dependent 
To investigate the function of exon 3 that encodes part of cell death. Furthermore, Omi/HtrA2 can induce apoptosis in 
the catalytic domain as well as exon 7 that encodes part of the a caspase-independent manner that relies entirely on its abil-
PDZ domain, a number of chimeric proteins were made. A ity to function as a serine protease in the cytoplasm of cells. 
schematic diagram of these proteins is shown in FIG. 13. This This observation suggests that the presence of specific sub-
list contains Omi/HtrA2 as well as D-Omi/HtrA2, Omi-li.3 50 strates for Omi/HtrA2 whose destruction and removal is part 
that lacks only the sequence encoded by exon 3 and Omi-li. 7 of the caspase-independent apoptotic process. Alternatively, 
that lacks the sequence encoded by exon 7. Furthermore, Omi/HtrA2 might activate a precursor pro-apoptotic protein 
several other constructs were made where the catalytic activ- through limited proteolytic cleavage. 
ity ofOmi/HtrA2 was destroyed by an S/ A substitution and an In order to identify substrates for Omi/HtrA2, the latest 
Omi/HtrA2 construct where both the catalytic and PDZ 55 technology in proteomics was used. Human kidney extracts 
domains have been replaced with the corresponding domains obtained from BioChain Institute, Inc. (Hayward, Calif.). 
ofL56/HtrA2. For example, in Omi-SA, the Ser 306 (s) was These extracts were already fractionated into: (a) kidney 
replaced withAla (A); Omi-L56 chimera is a construct where membrane associated proteins and (b) kidney cytoplasmic 
the N-terminus of Omi-HtrA2 including the AVPS motif was proteins. About 200 mg of extract was incubated in the pres-
fused to L56 protein form the amino acid 156-480. Omi-L56- 60 ence of bacterially made His-Omi-134-458. As controls, no 
S/ A is a mutated form ofomi-L56, where the Ser 328 has been enzyme was added nor was the ucf-101 inhibitor used. After 
mutated to Ala. All of these constructs were cloned into 30 min of incubation at 37° C., the reaction was stopped with 
EGFP-Nl vector. the conserved amino-terminal mitochon- an equal amount of SDS-PAGE buffer. Proteins were ana-
dria targeting sequence (MTS) is shown, this is followed by lyzed by 2-dimensional gel electrophoresis. This service was 
the catalytic domain (which includes the AVPS motif), the 65 done in Kendrick's lab (Madison, Wis.). This lab specializes 
catalyticadomainiffollowedbythePDZdomain.Allofthese in 2D PAGE and provides a service for academia (http:// 
proteins were expressed as fusions with the green fluorescent www.kendricklabs.com/). When the images of the 2D-gels 
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(2000) J Biol Chem, 275, 29772-8). If 14-3-3 proteins are 
indeed physiological substrates for Omi/HtrA2, it will help to 
explain how Omi/HtrA2 causes caspase-independent cell 
death. It has been reported that when the 14-3-35 protein (one 
of the seven 14-3-3 isoforms) was disrupted in a human 
colorectal cancer cell line, cells arrested in the G2 phase and 
ultimately perished by non-apoptotic cell death (Chan, et al. 
(1999) Nature, 401, 616-20). 
Annexin V is a vascular anticoagulant protein that is nor-
were compared, two polypeptides (32 kD and 291 W) in the 
human kidney cytoplasmic fraction were specifically cleaved 
by His-Omi (results not shown). This cleavage was prevented 
by the specific inhibitor ucf-101. It was also not seen when the 
enzyme was left out of the reaction. No proteins were cleaved 5 
in the membrane bound fractions. After scaling-up the reac-
tion, the two polypeptide spots were excised and sent to the 
Protein Chemistry Core Facility, Howard Hughes Medical 
Institute/Columbia University for mass spectrometry 
sequencing. 10 mally present on the cytosolic site of the plasma membrane 
(Tait, et al. (1988) Biochemistry, 27, 6268-76; and Reuteling-
sperger, et al. (1988) Eur J Biochem, 173, 171-8). Annexin V 
is a member of the calcium dependent phospholipid binding 
annexin/lipocortin protein family. It is composed of 320 
There, the proteins were identified as 14-3-3 protein and 
annexin V. 14-3-3 proteins are small acidic proteins with 
molecular mass ranging from 27 to 32 kDa with no detectable 
catalytic domain or function (Aitken, et al. (1995) Biochem 
Soc Trans, 23, 605-11; Dubois, et al. (1997) J Protein Chem, 
16, 513-22; Muslin, et al. (2000) Cell Signal, 12, 703-9; 
Shaw, (2000), Curr Biol, 10, R400; and Skoulakis, et al. 
(1998) Mal Neurobiol, 16, 269-84. 1998). 
There are seven identified 14-3-3 isoforms in mammals 
and these are highly conserved through evolution from the 
yeast to mammals. 14-3-3 proteins are phosphoserine-bind-
ing proteins involved in cellular proliferation, checkpoint 
control and apoptosis (Aitken, et al. (1995) supra). The mode 
ofaction of14-3-3 proteins is not due to any intrinsic activity. 
Instead, it relies entirely on the ability of 14-3-3 proteins to 
bind specific targets and modify their activity. For instance, 
14-3-3 binding to BAD competes with Bcl2 binding, reliev-
ing Bcl2 for its antiapoptotic function (Datta, et al. (2000) 
Mal Cell, 6, 41-51). 14-3-3 proteins canalsomodifythetarget 
protein localization (Muslin, et al. (2000) Cell Signal, 12, 
703-9), bridge two proteins together (Luo, et al. (1996) 
Nature, 383, 181-5), alter the catalytic activity of the target 
protein, or they can protect the target protein from modifica-
tions such as dephosphorylation (Chiang, et al. (2001) Blood, 
97, 1289-97). Approximately 70 target polypeptides for 
14-3-3 proteins have been identified so far (Tzivion, et al. 
<160> NUMBER OF SEQ ID NOS, 7 
<210> SEQ ID NO 1 
<211> LENGTH, 9 
<212> TYPE, PRT 
SEQUENCE LISTING 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
15 amino acid residues folded into a planar cyclical arrangement 
of four 70-amino acid repeats (Huber, et al. (1992) Behring 
Inst Mitt, 107-25). Most cells and tissues express annexin V 
(Kaetzel, et al. (1989) Biochem Biophys Res Commun, 160, 
1233-7). Some known activities of annexin V include col-
20 lagen binding (Pfaffie, et al. (1988) EMBO J, 7, 2335-42), 
formation of voltage dependent calcium charmels (Rojas, et 
al. (1990) J Biol Chem, 265, 21207-15) and inhibition of 
phospholipase A2 (Pepinsky, et al. (1988) J Biol Chem, 263, 
10799-811) and protein kinase C (Schlaepfer, et al. (1992) 
25 Biochemistry, 31, 1886-91 ). The high affinity ofannexin V for 
phospholipids has been exploited as a measure of apoptosis in 
a variety of cell types. Early apoptosis is characterized by 
exposure of phospholipids to the matrix side of the membrane 
(Fadok, et al. (1992) J Immunol, 148, 2207-16). Fluorescent-
30 labeled annexin V binding to the newly exposed phospholip-
ids is used to identify and quantitate apoptotic cells (Koop-
man, et al. (1994) Blood, 84, 1415-20; and Vennes, et al. 
(1995) J Immunol Methods, 184, 39-51). 
These data show that both 14-3-3 and Annexin V are 
35 cleared by Omi/HtrA2 and are physiological substrates of 
Omi/HtrA2. 
<223> OTHER INFORMATION, artificial protein sequence 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (5) .. (6) 
<223> OTHER INFORMATION, Xaa can be any naturally occurring amino acid 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (8) .. (9) 
<223> OTHER INFORMATION, Xaa can be any naturally occurring amino acid 
<400> SEQUENCE, 1 
Pro Arg Ala Ala Xaa Xaa Thr Xaa Xaa 
1 5 
<210> SEQ ID NO 2 
<211> LENGTH, 52 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Primer sequence 
<400> SEQUENCE, 2 
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-continued 
tcgaattcgc tgggggagga gacagtactg tctcctcccc cagcgaattt tt 
<210> SEQ ID NO 3 
<211> LENGTH, 53 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Primer sequence 
<400> SEQUENCE, 3 
taagcgaccc cctcctctgt catgacagag gagggggtcg cttaaaaatc tag 
<210> SEQ ID NO 4 
<211> LENGTH, 18 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Primer sequence 
<400> SEQUENCE, 4 
gcggggcggg gtgcaaac 
<210> SEQ ID NO 5 
<211> LENGTH, 17 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Primer Sequence 
<400> SEQUENCE, 5 
gacagccagc accgtgg 
<210> SEQ ID NO 6 
<211> LENGTH, 17 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Primer Sequence 
<400> SEQUENCE, 
ttcgttgccg gtccaca 
<210> SEQ ID NO 7 
<211> LENGTH, 18 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Primer sequence 
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What is claimed is: 
1. A pharmaceutical composition for inhibiting cellular 
apoptosis, the composition comprising at least one apoptosis 
inhibiting compound that can modulate caspase-independent 
apoptosis and a pharmaceutically acceptable carrier, wherein 






20 wherein Rl is selected from the group consisting of a nitro 
group, a carboxy group, a hydroxide, an aliphatic group, an 
aromatic group, an acyl group, an alkoxy group, an alkeylene 
group, an alkenylene group, an alkynylene group, a hydroxy-
carbonylalkyl group, an anhydride, an amide, an amine, and a 
25 
heterocyclic aromatic group, an wherein R2 is a methoxy 
group. 
30 
wherein Rl is selected from the group consisting of a nitro 
group, a carboxy group, a hydroxide, an aliphatic group, an 
aromatic group, an acyl group, an alkoxy group, an alkeylene 
group, an alkenylene group, an alkynylene group, a hydroxy- 35 
carbonylalkyl group, an anhydride, an amide, an amine, and a 
heterocyclic aromatic group. 
2. The pharmaceutical composition of claim 1 further com-
prising a pharmaceutical acceptable excipient. 
3. The pharmaceutical composition of claim 1, wherein the 40 
apoptosis inhibiting compound is 
~ s ~· 
~N~N~ 
45 
5. The pharmaceutical composition of claim 4, wherein the 
apoptosis inhibiting compound is 
Cl 




6. A pharmaceutical composition for inhibiting cellular 
apoptosis, the composition comprising at least one apoptosis 
inhibiting compound that can modulate caspase-independent 
apoptosis and a pharmaceutically acceptable carrier, wherein 
0 






4. A pharmaceutical composition, for inhibiting cellular 
apoptosis, the composition comprising at least one apoptosis 
inhibiting compound that can modulate caspase-independent 65 
apoptosis and a pharmaceutically acceptable carrier, wherein 
the apoptosis inhibiting compound has the structure: 
(III) 
US 8,242,122 B2 
39 40 
wherein Rl is selected from the group consisting of a nitro 
group, a carboxy group, a hydroxide, an aliphatic group, an 
aromatic group, an acyl group, an alkoxy group, an alkeylene 
group, an alkenylene group, an alkynylene group, a hydroxy-
carbonylalkyl group, an anhydride, an amide, an amine, and a 5 
heterocyclic aromatic group. 
9. The pharmaceutical composition of claim 8, wherein the 
apoptosis inhibiting compound is 
~ s ~· 
~N~N~ 7. The pharmaceutical composition of claim 6, wherein the 
apoptosis inhibiting compound is 
0 
0 













10. The pharmaceutical composition of claim 1, wherein 
the apoptosis inhibiting compound alters a functional activity 
ofOmi/HtrA2. 
11. The pharmaceutical composition of claim 1, wherein 
the apoptosis inhibiting compound inhibits Omi/HtrA2 pro-
teolytic activity. 
12. The pharmaceutical composition of claim 1, wherein 
the apoptosis inhibiting compound inhibits Omi/HtrA2 activ-
30 ity at least about 20% to about 90%. 
13. The pharmaceutical composition of claim 3, wherein 
the apoptosis inhibiting compound alters a functional activity 
ofOmi/HtrA2. 
14. The pharmaceutical composition of claim 4, wherein 
the apoptosis inhibiting compound alters a functional activity 
ofOmi/HtrA2. 
8. A pharmaceutical composition for inhibiting cellular 
apoptosis, the composition comprising at least one apoptosis 
inhibiting compound that can modulate caspase-independent 35 
apoptosis and a pharmaceutically acceptable carrier, wherein 
the apoptosis inhibiting compound has the structure: 15. The pharmaceutical composition of claim 5, wherein 
the apoptosis inhibiting compound alters a functional activity 
40 ofOmi/HtrA2. 
16. The pharmaceutical composition of claim 6, wherein 
the apoptosis inhibiting compound alters a functional activity 
(IV) of0mi/HtrA2. 
17. The pharmaceutical composition of claim 7, wherein 
45 the apoptosis inhibiting compound alters a functional activity 
ofOmi/HtrA2. 
18. The pharmaceutical composition of claim 8, wherein 
the apoptosis inhibiting compound alters a functional activity 
o ofOmi/HtrA2. 
50 19. The pharmaceutical composition of claim 9, wherein 
the apoptosis inhibiting compound alters a functional activity 
ofOmi/HtrA2. 
20. The pharmaceutical composition of claim 3, wherein 
the apoptosis inhibiting compound inhibits Omi/HtrA2 pro-
55 teolytic activity. 
21. The pharmaceutical composition of claim 4, wherein 
the apoptosis inhibiting compound inhibits Omi/HtrA2 pro-
teolytic activity. 
22. The pharmaceutical composition of claim 5, wherein 
60 the apoptosis inhibiting compound inhibits Omi/HtrA2 pro-
teolytic activity. 
wherein Rl is selected from the group consisting of a nitro 
group, a carboxy group, a hydroxide, an aliphatic group, an 
aromatic group, an acyl group, an alkoxy group, an alkeylene 
group, an alkenylene group, an alkynylene group, a hydroxy- 65 
carbonylalkyl group, an anhydride, an amide, an amine, and a 
heterocyclic aromatic group. 
23. The pharmaceutical composition of claim 6, wherein 
the apoptosis inhibiting compound inhibits Omi/HtrA2 pro-
teolytic activity. 
24. The pharmaceutical composition of claim 7, wherein 
the apoptosis inhibiting compound inhibits Omi/HtrA2 pro-
teolytic activity. 
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25. The pharmaceutical composition of claim 8, wherein 
the apoptosis inhibiting compound inhibits Omi/HtrA2 pro-
teolytic activity. 
26. The pharmaceutical composition of claim 9, wherein 
the apoptosis inhibiting compound inhibits Omi/HtrA2 pro- 5 
teolytic activity. 
27. The pharmaceutical composition of claim 3, wherein 
the apoptosis inhibiting compound inhibits Omi/HtrA2 activ-
ity at least about 20% to about 90%. 
10 
28. The pharmaceutical composition of claim 4, wherein 
the apoptosis inhibiting compound inhibits Omi/HtrA2 activ-
ity at least about 20% to about 90%. 
29. The pharmaceutical composition of claim 5, wherein 
the apoptosis inhibiting compound inhibits Omi/HtrA2 activ- 15 
ity at least about 20% to about 90%. 
30. The pharmaceutical composition of claim 6, wherein 
the apoptosis inhibiting compound inhibits Omi/HtrA2 activ-
ity at least about 20% to about 90%. 
31. The pharmaceutical composition of claim 7, wherein 20 
the apoptosis inhibiting compound inhibits Omi/HtrA2 activ-
ity at least about 20% to about 90%. 
32. The pharmaceutical composition of claim 8, wherein 
the apoptosis inhibiting compound inhibits Omi/HtrA2 activ-
25 
ity at least about 20% to about 90%. 
33. The pharmaceutical composition of claim 9, wherein 
the apoptosis inhibiting compound inhibits Omi/HtrA2 activ-
ity at least about 20% to about 90%. 
34. A pharmaceutical composition for inhibiting cellular 30 
apoptosis, the composition comprising at least two apoptosis 
inhibiting compounds that can modulate caspase-indepen-
dent apoptosis and a pharmaceutically acceptable carrier, 
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